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Abstract
Human Cytomegalovirus (HCMV) utilizes two different pathways for host cell entry. HCMV entry into fibroblasts requires
glycoproteins gB and gH/gL, whereas HCMV entry into epithelial and endothelial cells (EC) requires an additional complex
composed of gH, gL, UL128, UL130, and UL131A, referred to as the gH/gL-pentamer complex (gH/gL-PC). While there are no
established correlates of protection against HCMV, antibodies are thought to be important in controlling infection.
Neutralizing antibodies (NAb) that prevent gH/gL-PC mediated entry into EC are candidates to be assessed for in vivo
protective function. However, these potent NAb are predominantly directed against conformational epitopes derived from
the assembled gH/gL-PC. To address these concerns, we constructed Modified Vaccinia Ankara (MVA) viruses co-expressing
all five gH/gL-PC subunits (MVA-gH/gL-PC), subsets of gH/gL-PC subunits (gH/gL or UL128/UL130/UL131A), or the gB
subunit from HCMV strain TB40/E. We provide evidence for cell surface expression and assembly of complexes expressing
full-length gH or gB, or their secretion when the corresponding transmembrane domains are deleted. Mice or rhesus
macaques (RM) were vaccinated three times with MVA recombinants and serum NAb titers that prevented 50% infection of
human EC or fibroblasts by HCMV TB40/E were determined. NAb responses induced by MVA-gH/gL-PC blocked HCMV
infection of EC with potencies that were two orders of magnitude greater than those induced by MVA expressing gH/gL,
UL128-UL131A, or gB. In addition, MVA-gH/gL-PC induced NAb responses that were durable and efficacious to prevent
HCMV infection of Hofbauer macrophages, a fetal-derived cell localized within the placenta. NAb were also detectable in
saliva of vaccinated RM and reached serum peak levels comparable to NAb titers found in HCMV hyperimmune globulins.
This vaccine based on a translational poxvirus platform co-delivers all five HCMV gH/gL-PC subunits to achieve robust
humoral responses that neutralize HCMV infection of EC, placental macrophages and fibroblasts, properties of potential
value in a prophylactic vaccine.
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Introduction
HCMV infection causes morbidity and mortality in vulnerable
hosts following horizontal or vertical transmission [1]. In
immunosuppressed subjects, multi-system life-threatening disease
can occur with primary infection, reinfection by a different
HCMV strain, or after viral reactivation. HCMV is the most
common congenital infection worldwide (0.2–2.0% of all preg-
nancies) often resulting in long-term consequences to the
developing fetus including mortality [2,3]. Intrauterine HCMV
has a marked tropism for the developing central nervous system,
and a consequence of congenital infection can be irrevocable
neurological sequelae in newborns. Despite intensive research that
spans four decades, there is no licensed vaccine to prevent HCMV
infection [4,5]. In 1999, the Institute of Medicine ranked HCMV
infection in the highest category for vaccine preventable diseases
because potential societal benefits from reduction in associated
morbidity and mortality would far outweigh development costs
[6]. Development of an HCMV vaccine that efficiently confers
protection against primary HCMV infection or reinfection of a
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woman of child-bearing years by limiting horizontal transmission
is a candidate solution to significantly reduce the devastating
consequences of intrauterine HCMV infection [7].
A number of challenges have inhibited progress in HCMV
vaccine development [8]. HCMV vaccine strategies have been
guided, in large part, by historical precedents of currently licensed
vaccines demonstrating that induction of pathogen-specific B cell
immunity protects against infection and/or disease [9–11]. The
disappointing Phase 2 trial showing that HCMV hyperimmune
globulins are ineffective in the treatment of congenital HCMV
infection has renewed interest in eliciting NAb by an HCMV
vaccine [12–14]. Studies using fibroblasts as a cell substrate for
infection have demonstrated that the envelope glycoprotein B (gB)
is essential for HCMV entry [15–17]. gB elicits the majority of
antibodies in immune individuals that neutralize fibroblast
infection by blocking gB-mediated fusion between the virion
and cell membrane [18–23]. Importantly, pregnant women
who develop high avidity anti-gB NAb during primary infection
are less likely to give birth to an infant with congenital infection
compared to women who are initially CMV seronegative [24–
26]. These observations formed the rationale to focus HCMV
subunit vaccine design using gB [7,27,28]. A Phase II clinical
trial based on recombinant gB admixed in the adjuvant MF59
established a protection level of 50% against primary HCMV
infection among women who had given birth in the preceding
year [29]. gB adjuvanted in MF59 is the sole example of a
vaccine that has shown significant efficacy to protect healthy
women against primary HCMV infection and seronegative
solid organ transplant recipients from infection as a result of
receiving a seropositive donor organ [30]. These clinical results
provide evidence that a vaccine which targets major neutral-
izing epitopes may have a role in protection against primary
HCMV infection. Consequently there is a strong interest to
optimize vaccine strategies by identifying dominant viral targets
of the host immune response that will improve protective
efficacy [8].
While prior work highlights the importance of gB-specific
immune responses in limiting primary infection, recent discoveries
on viral entry conclude that NAb responses that prevent HCMV
infection of various non-fibroblast cell types, including endothelial,
epithelial cells (EC) and monocytes, are qualitatively different from
those blocking fibroblast infection [31–33]. A current model
proposes that HCMV entry into fibroblasts occurs by fusion at the
plasma membrane and depends on envelope glycoprotein
complexes composed of gB, gH/gL and/or gH/gL/gO [34–37].
Alternatively, HCMV entry into EC is mediated by endocytosis
and requires an additional glycoprotein complex consisting of
UL128, UL130, UL131A, and gH/gL, termed the gH/gL
pentamer complex (gH/gL-PC)[33,37–39]. Several studies pro-
vide evidence that gH/gL-PC is the dominant target of NAb in
sera from naturally HCMV positive individuals that prevents
HCMV infection of EC [31,40–44]. Significantly, the majority of
NAb in HCMV hyperimmune globulins (CMV-IVIg) are directed
against epitopes of gH/gL-PC [44]. In contrast to NAb targeting
epitopes of gB, gH/gL, or gM/gN that neutralize HCMV
infection of fibroblasts or EC with moderate potency, NAb that
recognize conformational epitopes of gH/gL-PC neutralize
HCMV infection of EC with unusually high potency [41]. In
addition, there is correlative evidence obtained by in vitro
measurements for NAb responses to gH/gL-PC which have
implications for the in vivo control of viral dissemination [45].
These data are consistent with previous studies showing that gH/
gL-PC is an important target of the host response to HCMV
infection, and induction of gH/gL-PC-specific NAb should be
evaluated as a potential component of an HCMV vaccine trial.
We demonstrated that vaccination of rhesus macaques (RM)
with a bacterial artificial chromosome (BAC)-derived MVA vector
co-expressing all five rhesus cytomegalovirus (RhCMV) orthologs
of HCMV gH/gL-PC elicits potent RhCMV-specific NAb
responses [46]. Based on this observation, we constructed a single
MVA that co-expressed all five HCMV gH/gL-PC subunits
derived from the clinical-like isolate, TB40/E which has both EC
and macrophage tropism [47]. This vector induced EC-specific
NAb titers in mice and RM that were orders of magnitude higher
than those induced by MVA expressing only gH/gL-PC subunit
subsets (gH/gL or UL128/UL130/UL131A), or solely gB. In
addition, MVA-gH/gL-PC elicited NAb preventing HCMV
infection of fibroblasts with titers comparable to those induced
by MVA expressing gH/gL or gB. NAb generated in RM by
vaccination with MVA-gH/gL-PC also inhibited infection of
placental macrophages called Hofbauer cells (HC) [48]. The
avidity of CMV-specific antibodies durably rose after MVA-gH/
gL-PC vaccination, indicating that the quality of responses is
consistent with protective immunity. These results describe a novel
vaccine strategy that induces high level NAb titers that interfere
with two prominent HCMV entry routes utilizing a single vaccine
vector, a possible requirement to prevent clinical HCMV
infection.
Results
Generation of MVA vectors expressing gH/gL-PC subunit
proteins or gB
We used as a model our recently described BAC-derived MVA
vaccine vector for RhCMV gH/gL-PC, to rapidly and efficiently
construct a single MVA vector expressing all five HCMV gH/gL-
PC subunits (see Materials and Methods and Figure 1A for details)
[46]. gH/gL-PC subunits were derived from HCMV TB40/E,
a well-characterized clinical-like HCMV strain with an intact
complement of gH/gL-PC genes [49]. Two versions of gH/gL-PC
Author Summary
Human cytomegalovirus (HCMV) fetal infection during
pregnancy and infection of immunocompromised patients
are both clinical problems considered extremely important
by the Institute of Medicine. Limited efficacy against
primary HCMV infection was found using a subunit vaccine
based on glycoprotein B, an important neutralizing
antibody determinant blocking HCMV entry into fibro-
blasts. The HCMV field has been transformed by the
discovery that a five-member (pentamer) protein complex
is a required factor for epithelial and endothelial cell entry
and indispensable for transmission as shown in non-
human primates. Targeting HCMV with antibodies specific
to the pentamer may interrupt horizontal and vertical
transmission. We describe an innovative vaccine strategy
to induce serum neutralizing antibodies of impressive
magnitude against HCMV in two animal models. Using an
attenuated poxvirus vector system, we demonstrate that
co-expression of all five pentamer components is signifi-
cantly more potent to induce serum neutralizing antibod-
ies than subunit subsets of the complex or glycoprotein B,
reaching peak levels comparable to HCMV hyperimmune
globulin. A vaccine that elicits systemic and mucosal
antibody responses that prevents infection of multiple cell
types crucial to natural history of HCMV infection could
play a role in preventing congenital HCMV infection and
control of infection in immunocompromised patients.
HCMV gH/gL-Pentamer Complex Vaccine
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vectors were constructed expressing either a full-length version of
gH (MVA-gH/gL-PC) or a variant of gH in which the
transmembrane (TM) and cytoplasmic domains were deleted
(MVA-gH/gL-PCD, Figure 1B). To provide a comparative basis
for evaluating the NAb responses elicited by immunization with
MVA-gH/gL-PC and MVA-gH/gL-PCD, MVA vectors express-
ing full-length gH/gL (MVA-gH/gL), UL128/UL130/UL131A
(MVA-UL128-131), full-length gB (MVA-gB), and TM-deleted gB
(MVA-gBD) were also constructed (Figure 1B and 1C). gO is
known to associate with gH/gL and to contribute to the
endoplasmic reticulum transport of these proteins, anchoring
either gH/gL or gH/gL/gO complexes within the virion envelope
[50,51]. We did not investigate co-expression of gH/gL and gO
because gO does not promote gH/gL cell surface expression, and
is therefore unlikely to aid in more effectively displaying gH/gL to
the immune system [36]. We also did not test a combination of the
gH/gL-PC and gO, since gO would likely compete with UL128,
UL130 and UL131A subunits to associate with gH/gL and, thus,
prevent or decrease the formation of gH/gL-PC and the induction
of potent EC specific NAb responses[36,50,51]. Full-length gH or
gB ORFs with an intact TM domain as well as their TM-deleted
versions were inserted between the essential ORFs G1L and I8R
of the MVA genome, an insertion site that is known to provide
stable propagation of large and/or unstable sequences (Figure 1B
and 1C)[52]. Vectors to express full-length or TM-deleted gH and
gB were constructed to test which complex, a membrane-tethered
or a soluble one would elicit the strongest NAb responses. Deletion
of the TM domain of gB has been shown to improve the protein
expression and the generation of NAb when compared to its full-
length counterpart [53,54]. MVA recombinants were reconstitut-
ed in baby hamster kidney (BHK) cells [46], and expanded to
generate virus stocks for in vitro and in vivo characterization.
Expression of gH/gL-PC or gB subunits from MVA
HCMV proteins that were expressed from all gH/gL-PC-
related vectors displayed sizes in agreement with published values
(Figure 2A)[33,39,55,56]. There was no discernible size difference
between full-length gH (MVA-gH/gL-PC and MVA-gH/gL) and
truncated gH (MVA-gH/gL-PCD), since the size difference of the
TM-deleted gH (DgH) and its full-length counterpart was only
fourteen amino acids (AA) taking into account deletion of the TM
and addition of the myc-tag (Figure 1B). Comparable levels of
expression for each of the gH/gL-PC components were found
from either the MVA-gH/gL-PC or MVA-gH/gL-PCD vectors
(Figure 2A). Expression levels of UL128, UL130, and UL131A
appeared to be slightly greater in MVA-UL128-131 than in either
MVA-gH/gL-PC or MVA-gH/gL-PCD. Of note, the MVA-
expressed BR5 antigen [57] used as a loading control had slightly
higher expression in both MVA-UL128-131 and MVA expressing
the fluorescent marker Venus [58] than any of the gH expressing
MVA vectors (Figure 2A). These small differences in expression
levels have not been explored further, and may reflect properties of
MVA and/or the protein subunits. Full-length gB harvested from
whole cells shows a 130 kDa precursor (PC) band, and a 55 kDa
Figure 1. Insertion of gH/gL-PC subunits or gB into MVA-BAC. A) Gene insertion using transfer vector. The transfer vector contains in the
indicated order a mH5 promoter, a multiple cloning site (MCS), and a transcription termination signal (TS). It further comprises a I-SceI recognition site
and a kanamycin resistance marker (KanR) both flanked by a 50 bp MVA sequence duplication (small black boxes). The entire construct is flanked by
two,700 bp sequences of the MVA insertion site (large green and red bars). Following cloning, the gene is inserted into the MVA-BAC via a first Red
recombination utilizing the large 700 bp sequence flanks. The selection marker is then removed after introduction of a double-strand break at the I-
SceI site and a second Red recombination between the 50 bp sequence duplication. B) Gene insertion sites. HCMV genes were inserted with the
indicated order (1-5) and 59-39 orientation into the MVA insertion sites Del2 (UL128), IGR3 (UL131), G1L/I8R (gH or gHDTM, or at the ends of the BAC
vector (B) within the Del3 insertion site (UL130 and gL). C) gB or gBDTM were separately inserted into the G1L/I8R insertion site. Thin horizontal lines
represent approximate lengths of either HCMV genes or portions of the MVA genome. Filled arrowheads in C indicate the cleavage site of the
precursor gB protein encoded by the gB or gBDTM gene cassette. AD1 designates antigenic domain 1, which is recognized by the anti-gB mAb 7-
17[112].
doi:10.1371/journal.ppat.1004524.g001
HCMV gH/gL-Pentamer Complex Vaccine
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band corresponding to the processed C-terminal (CT) fragment
(Figure 2B). The 110 kDa precursor form and a truncated C-
terminal (CT) cleavage product (35 kDa) were detectable in MVA-
gBD infected cells (Figure 2B). In summary, these data show that
MVA-BAC technology allows rapid generation of MVA express-
ing all five gH/gL-PC subunits with either gH or gHD, subunit
subsets (UL128-UL131A or gH/gL), gB or gBD proteins with
sufficient stability for animal vaccination.
Secretion of gH/gL-PC subunits or gB depends on
transmembrane deletion
We first investigated if deletion of the TM domain of gH led to
secretion of the gH/gL-PC subunits by performing immunoblot
analysis of concentrated serum-free medium from chicken embryo
fibroblasts (CEF) which are permissive for MVA infection. As
observed in infected BHK cells (Figure 2A), comparable levels of
the individual gH/gL-PC subunits were detectable in whole cell
lysates of CEF cells infected with MVA expressing subsets or all
5 gH/gL-PC subunits (Figure 2C;Cell). In contrast, efficient
secretion of all 5 gH/gL-PC subunits was only detectable in the
medium of CEF cells infected with MVA-gH/gL-PCD (without
gH TM); whereas none of the subunits were detected in the
medium of MVA-gH/gL-PC (with gH TM) infected CEFs
(Figure 2C; Med). In addition, gH or gL was not detectable in
the medium of MVA-gH/gL (with gH TM) infected CEFs. In the
case of MVA-UL128-131, only small amounts of UL130 and
UL131A were observed in the medium of MVA-UL128-131
infected cells, though UL128 was undetectable (Figure 2C). These
data indicate that deletion of the gH TM promotes efficient
secretion of all 5 gH/gL-PC subunits, whereas maintenance of the
gH TM retains the gH/gL-PC subunits or gH/gL in the cell or on
the cell surface when co-expressed from MVA. Therefore, we
believe that the data implicates the gH TM as a pivotal structure
for the co-localization of all five gH/gL-PC subunits on the cell
surface, and in the absence of the gH TM, the complex is secreted
into the medium from the MVA-infected cell (Figure 2C).
Presumably, the scaffold properties of the gH protein allow
assembly of the full five member complex anchored to the cell
surface. We also investigated the impact of TM deletion on
secretion of the gB protein. Protein species corresponding to the
precursor and the C-terminal fragments of gB and gBDTM in
lysates of MVA-gB or MVA-gBD infected CEFs were similar to
those found in BHK cells (Figure 2B and D; Cell). However, only
the cleavage product of the gBDTM protein was detectable in the
medium from gBD-MVA-infected CEF (Figure 2D, Med). We
hypothesize that the gB TM tethers the full-length or precursor
forms of gB onto the cell surface which limits the secretion of these
forms of gB from MVA-gB infected cells.
Complex formation of gH/gL-PC subunits expressed from
MVA
We examined if multi-protein complexes were formed by
expression of gH/gL-PC from MVA-gH/gL-PC, gH/gL ex-
pressed from MVA-gH/gL or UL128-UL130-UL131A expressed
from MVA-UL128-131, and characterized their subunit compo-
sition using co-immunoprecipitation (co-IP) with two different
antibody (Ab) preparations. Using the monoclonal antibody (mAb)
11-1-1 to HCMV gH [59] to isolate protein complexes containing
gH, all five gH/gL-PC subunits were immunoprecipitated from
BHK cells infected with MVA-gH/gL-PC, and gH/gL proteins
were immunoprecipitated from cells infected with MVA-gH/gL
(Figure 3A). As expected, the UL128-UL131A proteins expressed
from MVA-UL128-131 were not immunoprecipitated by the anti-
gH mAb. Similar to the gH antibody results, polyclonal antibodies
to UL130 immunoprecipitated all five gH/gL-PC subunits from
BHK cells infected with MVA-gH/gL-PC (Figures 3A and B). As
expected, gH/gL protein complexes expressed from MVA-gH/gL
were not immunoprecipitated by UL130 polyclonal antibodies,
though UL128, UL130 and UL131A proteins expressed from
MVA-UL128-131 were immunoprecipitated by UL130 antisera
(Figure 3). In comparison to the immunoprecipitated proteins
from MVA-gH/gL-PC, higher amounts of gH/gL were confirmed
following IP of gH from MVA-gH/gL infected cells, and of
UL128, UL130, and UL131A after IP of UL130 from cells
infected with MVA-UL128-131. This difference in immunopre-
cipitated gH/gL or UL128-131A proteins can be explained by
differing protein amounts extracted from MVA-gH/gL-PC
Figure 2. Expression of gH/gL-PC subunits and gB from MVA.
Whole cell lysates of BHK cells or whole cell lysates and concentrated
serum-free medium of CEF cells infected with the indicated MVA
recombinants were analyzed by Immunoblot. gH/gL-PC subunits were
detected with anti-HCMV gH mAb 11-1-1 and rabbit polyclonal antisera
to UL128, UL130, UL131A, and gL. gB proteins were detected with anti-
gB HCMV mAb 7-17, recognizing the C-terminal fragment of gB
(Figure 1C). A and B) Immunoblot detection of gH/gL-PC subunits (A)
or gB proteins (B) in MVA-infected BHK cells. C and D) Immunoblot
detection of gH/gL-PC subunits (C) or gB proteins (D) in cell lysates
(Cell) and concentrated medium (Med) of CEF cells infected with the
MVA recombinants. MVA expressing the fluorescent marker Venus was
a control (ctrl.) in A-D. Vaccinia virus BR5 was detected in the samples as
loading control. PC = precursor protein; CT = C-terminal cleavage
product of gB.
doi:10.1371/journal.ppat.1004524.g002
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infected cells in comparison to proteins extracted from cells
infected with MVA-gH/gL or MVA-UL128-131, respectively
(input; Figure 3A and 3B). HCMV proteins were not immuno-
precipitated by an IgG control Ab (Figure 3A) or rabbit polyclonal
pre-immune serum (Figure 3B), confirming the specific co-IP of
individual gH/gL-PC subunits by the gH mAb or UL130
antiserum. The major conclusions from these observations were
that (1) four other gH/gL-PC subunits associate either directly or
indirectly with gH or UL130 and are pulled down with anti-gH or
anti-UL130 antibodies when co-expressed from MVA-gH/gL-PC,
(2) gL interacts with gH when co-expressed from MVA-gH/gL,
and (3) UL128-UL130-UL131A interact with each other when
expressed by MVA-UL128-131. Together, these data indicate that
all three MVA constructs can express HCMV proteins capable of
forming complexes, at least when cell-associated.
Secretion of gH/gL-PCD complexes from MVA-gH/gL-
PCD infected BHK cells.
An important result would be to demonstrate that the subunits
that compose gH/gL-PCD physically associate with each other to
form a secreted complex. To determine if the complex that was
released into the medium of cells infected with MVA-gH/gL-PCD
contained all five gH/gL-PC subunits, we performed co-IP using
concentrated medium harvested from MVA-gH/gL-PCD infected
CEF. IP was carried out either using mAb 11.1.1 to gH
(Figure 3C) or rabbit polyclonal antiserum to UL130 (Figure 3D),
with a similar result that all 5 subunits were shown to associate by
co-IP. While the gH mAb was more efficient in detecting and
precipitating the gH/gL-PC than the polyclonal antiserum to
UL130, the qualitative result was the same, which shows evidence
that the secreted form of the gH/gL-PCD is maintained as an
intact complex in the cell culture medium.
TM-dependent cell surface expression of gH/gL-PC
Next, we investigated whether the efficient transport of gH
complexes (gH/gL-PC, gH/gL-PCD, or gH/gL) to the cell surface
depends on the TM of the gH subunit (Figure 4A). BHK cells
infected with MVA recombinants were analyzed by flow
cytometry (FC) using the anti-gH Ab 14-4b to evaluate cell
surface expression of the gH subunit with or without its TM
domain. Cells infected with MVA-gH/gL-PC showed higher
expression of cell-surface gH than other infected samples and the
control cells (Figure 4A). The minimal detection of cell-surface gH
on MVA-gH/gL-PCD-infected cells (Figure 4A), may reflect
Figure 3. Complex formation of gH/gL-PC subunits co-expressed from MVA. Cell lysates of BHK cells (prepared under non-denaturing
conditions) or concentrated serum-free medium of CEF infected with MVA recombinants were subjected to co-IP with anti-HCMV gH mAb 11-1-1 or
UL130 polyclonal antiserum. Immunoprecipitated gH/gL-PC subunits were detected with anti-gH mAb 11-1-1 and UL128, UL130, UL131A, and gL
rabbit polyclonal antisera. A and B) Immunoblot detection of gH/gL-PC subunits after co-IP from BHK cells infected with MVA-gH/gL-PC, MVA-gH/gL,
or MVA-UL128-131. C and D) Immunoblot detection of gH/gL-PC subunits following co-IP from concentrated medium of MVA-gH/gL-PCD-infected
CEF cells. Irrelevant mouse IgG Ab and rabbit UL130 pre-immune serum were used for IP controls (ctrl.). IgGHC or IgGLC = Immunoglobulin G heavy or
light chains. Input in A-D = detection of gH/gL-PC subunits in the samples subjected to co-IP.
doi:10.1371/journal.ppat.1004524.g003
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transit of soluble complexes through the plasma membrane, rather
than actual cell-surface expression. As expected, cell surface
expression of gH was detected on MVA-gH/gL-infected cells,
although at a lower density than on MVA-gH/gL-PC infected
cells, consistent with previous observations that the transport of gH
to the cell-surface is more efficient when all 5 gH/gL-PC subunits
are co-expressed in comparison to only gH and gL [39]. We
confirmed the FC results that we obtained with the anti-gH mAb
by using the same rabbit polyclonal Ab preparation specific for
UL130 that was used in the co-IP experiments in Figure 3. Cell
surface UL130 antigen was detected on MVA-gH/gL-PC infected
cells, although not on cells infected either with MVA-gH/gL-PCD
or MVA-gH/gL (Figure 4B). UL130 was also detectable on cells
infected with MVA-UL128-131 with comparable density to that
observed for MVA-gH/gL-PC (Figure 4B). GFP expression
quantified by its fluorescence properties was used to demonstrate
equal infection of cells by all MVA vectors examined in Figure 4A
and B (data not shown). BAC derived MVA expressed GFP due to
the vector construction [60]. Collectively, these results indicate
that gH and UL130 are transported to the cell surface when all
five gH/gL-PC subunits are co-expressed from MVA when gH
contains a TM. Further proof is needed to establish if gH and
UL130 are expressed on the cell surface in a complex with UL128,
UL131A, and gL. Nonetheless, as shown by the secretion
experiment in Figure 3C and D, complexes composed of all five
gH/gL-PC subunits are secreted and not cell-surface associated
when the gH TM is deleted. Further work is needed to explain
how UL130 is transported to the cell surface in the absence of gH/
gL.
IF demonstrates cellular localization of gH/gL complexes
is dependent on presence of TM
We utilized immunofluorescence (IF) to detect surface expres-
sion of gH on BHK cells infected with MVA-gH/gL-PC, MVA-
gH/gL-PCD or MVA-gH/gL by staining with anti-gH HCMV
mAb 14-4b. We permeabilized MVA-infected cells to facilitate
intracellular Ab penetration. This enabled labeling of internal
cytoplasmic proteins to compare with the results of Ab labeling of
non-permeabilized cells. Consistent with the FC data (Figure 4A),
cell surface staining of gH without permeabilization was only
observed for constructs expressing TM containing glycoprotein
complexes (MVA-gH/gL-PC and MVA-gH/gL Figure S1; non-
permeabilized). In contrast, only a few cells infected with MVA-
gH/gL-PCD showed staining for gH with less intensity when
compared to MVA-gH/gL-PC infected cells, which may reflect
TM-deleted gH protein transitioning through the plasma mem-
brane or intracellular penetration of the gH Ab through leaky cell
membranes (Figure S1). However, when cells infected with any of
the three constructs were permeabilized, the signal was brighter
and emanated prominently from the cytoplasm. The effect is most
prominent in the case of MVA-gH/gL-PCD, but clearly visible
with either MVA-gH/gL or MVA-gH/gL-PC infected cells. GFP
expression was monitored to localize areas of viral foci. As shown
in the control panel (Figure S1), most nuclei were intensely stained
with an anti-Histone 3 Ab when cells were permeabilized, while
only a few scattered nuclei were stained with less intensity in non-
permeabilized cells. This indicates that only permeabilization
allowed intracellular Ab entry, whereas non-permeabilized cells
were resistant to Ab entry. We were unable to effectively use the
UL130 polyclonal antiserum for IF studies to replicate the results
we found with the anti-gH mAb; therefore we cannot conclude
that UL130 is present on the cell-surface alone or as part of a
protein complex using the IF approach (data not shown). Direct
evidence that gH with a TM is associated with the other four gH/
gL-PC subunits will require further study with Ab reagents that
bind to cell-surface forms of these proteins.
gH/gL-PC subunits co-expressed from MVA elicit murine
NAb blocking HCMV infection of EC
Vaccination of mice using MVA recombinants was performed
to evaluate which combination of HCMV antigens induced NAb
that prevented in vitro HCMV infection of ARPE-19 epithelial
cells and human umbilical vein endothelial cells (HUVEC). Mice
were vaccinated three times (0, 4, and 8 weeks) by the
Figure 4. Cell surface detection of gH and UL130 expressed from MVA recombinants. BHK cells infected with MVA recombinants were
analyzed by FC for cell surface staining of gH or UL130. Staining was performed with mouse anti-HCMV gH mAb 14-4b or UL130 rabbit antiserum as
primary antibodies and fluorophore-coupled secondary Ab anti-mouse or anti-rabbit Alexa Fluor 647. A) FC analysis of cell surface staining of gH on
BHK cells infected with the indicated gH/gL-PC-related vectors. B) FC analysis of cell surface staining of UL130 on BHK cells infected with the
indicated gH/gL-PC-related vectors. Cells infected with MVA-Venus were analyzed as a control.
doi:10.1371/journal.ppat.1004524.g004
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intraperitoneal (i. p.) route (Figure 5A) and the NAb titer that
blocked 50% infection (NT50) of HCMV strain TB40/E was
evaluated on human ARPE-19 cells [49]. Marked differences were
noted in the ability of different vectors to induce NAb. Only
MVA-gH/gL-PC and MVA-gH/gL-PCD stimulated high NAb
titers that blocked TB40/E infection of ARPE-19 cells (peak titers
.62,000; Figure 5B and Table S1). NAb titers in MVA-gH/gL-
PC vaccinated mice were detectable after the initial vaccination,
increased to maximum NT50 levels after the first boost, and only
slightly declined following the second boost (Figure 5B and Table
S1). However, the kinetics of reaching peak NAb titers in
MVA-gH/gL-PCD vaccinated mice were quite different. NAb
were undetectable following the initial vaccination, but increased
to maximum NT50 levels after two boosts (peak titers .62000;
Figure 5B and Table S1). Substantially lower titers were observed
with MVA-gH/gL (peak titer = 2,170) and lower yet with MVA-
gBD (peak titer = 250). No EC NAb were stimulated with MVA-
UL128-131 or MVA-gB (Figure 5B). In a repeat experiment
examining MVA-gH/gL-PC, high titer NAb were stably elevated
over a period of at least fifty weeks after initial vaccination
(Figure 5F). In experiments conducted with HUVECs using the
identical methods, we found almost identical results as document-
Figure 5. NAb induction by MVA recombinants in mice. Balb/C mice were vaccinated three times by intraperitoneal (i.p.) route with MVA
recombinants. HCMV-specific serum NAb titer (NT50) was determined at different time points post-vaccination. A) Schematic of time line for MVA
vaccinations and serum sample collection. B-D) Shown are NT50 titers (geometric mean titer (GMT); n = 4) of vaccine groups measured at different
time points on ARPE-19 cells against TB40/E (B), at week 11 on ARPE-19 cells against different HCMV strains (TB40/E, TR, VHL/e) (C), or at week 16 on
ARPE-19 cells and HUVECs against TB40/E (D). E) NT50 titers measured on MRC-5 fibroblasts against TB40/E in the same samples as in B. F) Serum
NT50 titers in MVA-gH/gL-PC-vaccinated mice (GMT; n = 8) measured on ARPE-19 and MRC-5 cells against TB40/E over one year (n = 4 at week 50
(asterisks)). Significance bars (Sig. dif.) in B and E indicate points of significance at p=0.05. Dotted lines in all panels indicate the detection limit of the
assay. Upper bars represent 95% confidence intervals.
doi:10.1371/journal.ppat.1004524.g005
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ed on ARPE-19 cells (Figure 5B-D, F) using week seven (data not
shown) and week sixteen (Figure 5D) serum. Both gH/gL-PC
expression constructs, either with or without gH TM, induce
comparable peak NAb levels, but these titers are more rapidly
induced with a membrane-anchored form than with a TM deleted
form of the gH/gL-PC. The impact of the TM on the kinetics of
the NAb response is noteworthy as it may reflect a reduced
capacity by the immune system to generate a rapid humoral
response to a secreted form versus the cell surface form of the gH/
gL-PC. Ultimately, after three vaccinations, both forms of the
complex support the development of equivalent levels of NAb.
MVA- gH/gL-PC vaccinated mice generate immune sera
that detect heterologous HCMV strains
Since UL128-UL131A are highly conserved proteins among
different HCMV strains [61], NAb recognizing them should
neutralize different HCMV strains with comparable potency. We
performed neutralization assays on ARPE-19 cells using the
TB40/E, TR [62] and VHL/e [63,64] strains of HCMV for
infection. The five proteins that compose the gH/gL-PC of TB40/
E and TR have protein sequences which are .97% identical
(Accession # EF999921 and KF021605). Sequence information
for the clinical-like VHL/e strain is unavailable. There is sufficient
sequence variability in the gH amino acid sequence to define two
separate clusters of gH sequences designated as gH-group 1 and
group 2 (Figure S2). The strains that we investigated in Figure 5C
are each assigned to a separate gH group (Figure S2). Yet, serum
antibodies generated against TB40/E proteins expressed from
MVA neutralized group 1 (TR) and 2 (TB40/E) gH strains
equivalently (Figure 5C). In fact, MVA-gH/gL-PC and MVA-
gH/gL-PCD induced equivalent NAb titers against all three
HCMV strains, reaching NT50 levels .30,000 (Figure 5C).
Similarly, MVA-gH/gL elicited comparable NAb titers against
all three strains, although all were markedly lower than those
generated following immunization with either MVA-gH/gL-PC
or MVA-gH/gL-PCD (Figure 5C). MVA-UL128-131, MVA-gB,
or MVA-gBD did not stimulate detectable EC-specific NAb in this
experiment. These data indicate that MVA-gH/gL-PC and MVA-
gH/gL-PCD elicit high titer NAb, and far greater than MVA-gH/
gL to prevent HCMV infection of EC with heterologous HCMV
isolates with limited gH/gL-PC sequence diversity.
Co-expressed gH/gL-PC subunits induce NAb that
prevent HCMV infection of fibroblasts
We discovered that an MVA expressing all five RhCMV
orthologs of HCMV gH/gL-PC induced robust NAb responses
that prevented RhCMV infection of rhesus EC and fibroblasts
[46]. That was the premise for investigating if the mice that were
vaccinated with MVA expressing HCMV gH/gL-PC developed
NAb that blocked HCMV TB40/E infection of MRC-5
fibroblasts. Measurable NAb titers were generated following
vaccination of mice with all MVA recombinants, except MVA-
UL128-131 (Figure 5E and Table S1). NAb induced by MVA-
gH/gL-PC and MVA-gH/gL were comparable in titer and
kinetics (peak titers .1000; Table S1). NAb titers induced by
MVA-gH/gL-PC were stable over a period of twenty weeks
following the second boost (Figure 5F). In contrast, NAb titers
from MVA-gH/gL-PCD infected mice were undetectable after the
initial vaccination, but increased to levels comparable to those
induced by MVA-gH/gL-PC in response to two boosts (Figure 5E
and Table S1). NAb titers of mice vaccinated with MVA-gB kept
pace with MVA-gH/gL-PC vaccinated mice, but titers dropped to
baseline at the conclusion of the experiment (sixteen weeks). Mice
vaccinated with MVA-gBD developed NAb titers (peak
titers = 510) that were lower than all other vaccine groups except
MVA-UL128-131 which failed to induce any measurable NAb
titer, identical to its behavior in the EC system (Figure 5B and
Table S1). Collectively, these results emphasize the biologic
importance of the MVA-gH/gL-PC vaccine and highlight
immunologic differences in potency of sera from mice vaccinated
with different MVA constructs to neutralize HCMV infection of
fibroblasts and EC.
MVA-gH/gL-PC induces high NAb titers in vaccinated RM:
EC neutralization
We performed vaccinations studies in RM to investigate NAb
induction by MVA-gH/gL-PC or MVA-gH/gL in an animal
model that is evolutionarily closely related to humans. RhCMV-
uninfected RM were immunized three times with MVA-gH/gL-
PC, MVA-gH/gL or MVA-Venus (four RM per group)
(Figure 6A). We chose MVA-gH/gL-PC instead of MVA-gH/
gL-PCD because the full-length version of gH/gL-PC produced
higher titer NAb with faster kinetics than with TM-deleted gH in
our mouse experiments (Figure 5B and E). All MVA vaccines were
well-tolerated with no evidence of local injection site or systemic
reaction (data not shown). Both MVA-gH/gL and MVA-gH/gL-
PC stimulated EC- and fibroblast-specific NAb responses in RM,
and, as observed following vaccination in mice, notably higher EC
titers were elicited with MVA-gH/gL-PC than with MVA-gH/gL
(Figure 6B-F; Table S2). EC-specific NAb were detected in all four
vaccinated RM at the time of the first booster immunization with
MVA-gH/gL-PC (six weeks), and anamnestic responses were
observed after the booster immunizations at weeks six and twelve
(Figure 6B and F). Memory NAb responses were stimulated after
two booster immunizations with MVA-gH/gL (Figure 6D and F),
but peak titers (150–530; Table S2) were two orders of magnitude
less than those generated with MVA-gH/gL-PC (29,960–78,340,
Table S2). NAb titers declined for both MVA-gH/gL-PC and
MVA-gH/gL, but one distinction for MVA-gH/gL-PC was that
NAb titers declined to a plateau, and remained elevated fourteen
weeks after the second booster at week twelve (Figures 6B and F,
Table S2). In contrast, EC NAb titers declined to background over
the same time frame in animals immunized with MVA-gH/gL
(Figures 6D and F). Progressive declines in NAb titers down to the
limit of detection are a common observation in RM vaccinated
with DNA vaccines or viral vectors [43,46], and the sustainability
of EC-specific NAb after MVA-gH/gL-PC vaccination is a
notable exception to this pattern. We also investigated if serum
from RM that was active on ARPE-19 cells could neutralize
HCMV infection of HUVECs (Figure 6G). Similar to the case of
immune mouse serum (Figure 5D), NT50 titers on HUVECs were
almost identical to what we measured on ARPE-19 cells, showing
that neutralization extends to both epithelial and endothelial cell
types with an almost identical pattern and sensitivity.
MVA-gH/gL-PC induces high NAb titers in vaccinated RM:
Fibroblast neutralization
Sera from monkeys vaccinated with MVA-gH/gL-PC or MVA-
gH/gL were tested for NAb that prevented HCMV TB40/E
infection of MRC-5 fibroblasts. As observed in mice, MVA-gH/
gL-PC and MVA-gH/gL induced comparable fibroblast-specific
NAb titers in vaccinated RM (peak titers 190–630 and 100–310,
respectively) (Figures. 6C, E, and F; Table S2). Two injections
were required to stimulate detectable NAb with both vectors. As
with NAb that interfered with HCMV infection of EC,
comparable NAb interfering with fibroblast infection progressively
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Figure 6. HCMV-specific serum NAb titers in vaccinated RM. Groups of four RM were vaccinated three times with MVA recombinants by
intramuscular (i.m.) injection. HCMV-specific serum NT50 titers were determined at multiple time points on ARPE-19 cells, MRC-5 fibroblasts and
HUVEC using HCMV TB40/E for infection. A) Schedule for vaccination and sample preparation. B-E) Serum NT50 titer of individual RM vaccinated with
MVA-gH/gL-PC (B, C) or MVA-gH/gL (D, E) measured on ARPE-19 and MRC-5 cells. F) Comparison of serum NT50 titers determined in MVA-gH/gL-PC
or MVA-gH/gL vaccine groups (GMT; n = 4) on ARPE-19 and MRC-5. Serum from RM vaccinated with MVA-Venus was analyzed as a control. G) Serum
NT50 titer in vaccine groups (GMT, n= 4) measured on ARPE-19 cells and HUVECs at weeks 8 and 26 post-initial vaccination. Filled arrowheads
indicate vaccinations. Dotted lines represent detection limits. Upper bars represent 95% confidence intervals.
doi:10.1371/journal.ppat.1004524.g006
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declined after the first and second booster. While the second
booster stimulated NAb titers, peak titers after the second boost
did not reach those observed after the first boost, and NAb titers
were below or at the level of detection within six weeks of the
second boost (eighteen weeks). These data confirm in RM that
MVA-gH/gL-PC induces NAb that prevent HCMV infection of
fibroblasts with levels comparable to those induced by MVA-gH/
gL. Moreover, these data extend our mouse results in a primate
host and demonstrate that MVA expressing all five gH/gL-PC
subunits induce high titer HCMV-specific NAb. Detection of
ARPE-19 specific NAb titers that exceed those measured on
fibroblasts is consistent with observations made with HCMV-
positive human sera [44,65]. We note that NAb titers measured on
fibroblasts are significantly higher using MVA constructs express-
ing gH/gL or gH/gL-PC than control sera. Nevertheless, they are
far lower than those measured for ARPE-19 and HUVEC cells
using identical sera.
MVA-gH/gL-PC induced higher NAb titer than HCMV
positive serum preparations
To better gauge the magnitude of the immune responses
generated in vaccinated mice and RM, NAb titers were compared
to a pool of HCMV seropositive sera, commercially available
HCMV IgG sera, human intravenous immunoglobulin (IVIg) and
CMV-IVIg preparations which all should be considered as arising
from chronically infected individuals. NAb titers induced by
MVA-gH/gL-PC in mice and RM markedly exceeded EC-specific
NAb titers of three individual HCMV seropositive samples, a pool
of seven seropositive donors (Pool HCMV+), and IVIg (Figure 7).
Peak NAb titers generated in vaccinated RM and mice were
similar to the titer of CMV-IVIg in sera from chronically infected
humans. These titers were likely lower than immediately after
primary infection. Together, these results indicate that MVA-gH/
gL-PC boosts EC-specific NAb titers in two species to levels higher
than those measured in pooled sera from chronically HCMV-
positive humans and to comparable levels measured from
concentrated hyperimmune sera (CMV-IVIg) [40,66].
MVA-gH/gL-PC mediated neutralization of HCMV entry
into placental macrophages
It is hypothesized that maternal Ab plays an important role to
prevent virus transmission to the fetus[67,68], therefore we
investigated neutralization of HCMV on human placental
macrophages using sera from vaccinated RM described in
Figure 6. Hofbauer cells (HC) are specialized placental macro-
phages which enter the venous circulation of the placenta and
could act as a reservoir to transmit HCMV infection to the fetus
[69–72]. We evaluated whether MVA-gH/gL-PC induces in-
creased NAb responses to block HCMV TB40/E infection of
freshly isolated HC in comparison to the standard ARPE-19 EC
cell line. As shown in Figure 8 and Table S3, NAb titers induced
by MVA-gH/gL-PC in RM were significantly higher than those
determined from MVA-gH/gL or Venus control sera as measured
in both HC and ARPE-19 cells. Yet, sera from RM vaccinated
with MVA-gH/gL-PC had statistically indistinguishable NAb
titers when measured on HC and ARPE-19 cells, confirming that
HCMV entry into both cell types is blocked with similar potency
by gH/gL-PC specific NAb (Figure 8). Thus, we have demon-
strated for the first time that infection of HC by HCMV in vitro
can be blocked with serum antibodies generated against antigen-
specific targets such as gH/gL-PC. Future studies with other
critical decidual and/or placental cells such as cytotrophoblasts
Figure 7. NAb in vaccinated animals and HCMV-positive human sera. NT50 titers were measured on ARPE-19 cells against TB40/E infection
using commercially available HCMV IgG positive human sera (SeraCare Cat# 4234, 4360, 4371), HCMV pooled positive human sera (Pool HCMV+), IgG
preparations (IVIg and CMV-IVIg), and in MVA-gH/gL-PC vaccinated animals after the first boost. Bars represent standard deviation of three
independent experiments.
doi:10.1371/journal.ppat.1004524.g007
HCMV gH/gL-Pentamer Complex Vaccine
PLOS Pathogens | www.plospathogens.org 10 November 2014 | Volume 10 | Issue 11 | e1004524
should be attempted to conduct a fuller evaluation of placental
cells whose HCMV infection is neutralized by gH/gL-PC Ab.
MVA-gH/gL-PC vaccinated RM contain low levels of EC
specific NAb in saliva
Horizontal transmission of HCMV, including primary infection
during pregnancy, is thought to occur by mucosal exposure to
infectious virions. Vaccine-induced mucosal immunity may be
especially relevant for limiting the potential of mucosally acquired
virus from disseminating to distal sites, such as the maternal-fetal
interface. We measured NAb in saliva of RM vaccinated with
MVA-gH/gL-PC as a potential protective mechanism, based on
the premise that oral acquisition of virus is an important route of
primary infection [73]. Saliva of RM vaccinated with MVA-gH/
gL-PC or MVA-gH/gL was tested for the presence of NAb that
prevented HCMV TB40/E infection of ARPE-19 cells. Two of
four RM vaccinated with MVA-gH/gL-PC had measurable levels
of NAb in saliva following the first and second boost (Figure 9A
and Table S4). In contrast to serum NAb responses induced by
MVA-gH/gL-PC showing maximum NT50 levels after the first
boost, saliva NAb titers were highest (NT50 of 87.0 to 99.0) after
the second boost (Figure 9A and Table S4). However, saliva NAb
were not maintained at peak levels and dropped gradually until
they were undetectable ten weeks after the second boost. RM
vaccinated with MVA-gH/gL or MVA-Venus did not have
measurable NAb titers in saliva (Figure 9A and Table S4). In
addition, we did not detect saliva NAb that blocked HCMV
infection of MRC-5 fibroblasts in both MVA-gH/gL-PC and
MVA-gH/gL vaccine groups (data not shown).
Mucosal IgA and transudated IgG in oral saliva samples
from RM
To investigate whether neutralizing activity in the oral samples
of immunized RM could be attributed to transudated IgG or
mucosal IgA, we evaluated total and HCMV-specific IgG and IgA
levels in these samples. While total Ab levels in the oral swab
samples varied over time (Figure S3), probably due to the influence
of a number of variables [74], only MVA-gH/gL-PC immunized
RM showed an increase in mucosal HCMV-IgA in the oral swab
samples (Figure 9B). In contrast, HCMV-IgG levels in the same
samples were quite low for both MVA-gH/gL-PC and MVA-gH/
gL immunized RM (Figure 9C). In addition, none of the MVA-
gH/gL immunized RM had measurable HCMV-specific NAb in
saliva, so peaks were without interpretable significance (Fig-
ure 9A). Analysis of HCMV-IgG and HCMV-IgA Ab level
variation indicates that neutralizing activity observed in RM1
oral swab samples might be attributed to mucosal IgA (Figure
S3C) while that of RM3 to transudated IgG (Figure S3G). RM2
showed an interesting peak in HCMV-IgA but we could not detect
any neutralizing activity in the same samples (Figure S3C). Despite
the small number of animals used in this study, the results
strengthen the relevance of the vaccine as a tool to induce oral
secretion of IgG/IgA Ab. These results show that MVA-gH/gL-
PC induces EC-specific NAb responses in saliva following
vaccination of RM, which is consistent with NAb responses in
saliva of HCMV-seropositive individuals [73].
Measurement of HCMV-specific Ab avidity in sera from
vaccinated mice and RM
High avidity HCMV-specific IgG were found to be inversely
correlated with transmission of HCMV to the fetus [12,70,75].
Therefore, we investigated avidity maturation in immunized
animals using an established assay based on measurement of
comparative stability of Ab:antigen complexes in the presence or
absence of 6 M urea [76,77]. With the exception of the MVA-
Venus group, mice belonging to all other vaccine groups
developed binding antibodies to HCMV that were stable over
sixteen-weeks (Figure 10A). In contrast to animals vaccinated with
MVA expressing gB, gBD, or UL128/130/131, all gH-related
vaccine groups showed an increase in avidity index (AI) when
comparing three weeks after the first boost (week seven) to the end
(week sixteen) of the observation period (Figure 10B). In contrast,
HCMV-specific IgG levels in RM immunized with MVA-gH/gL-
PC and MVA-gH/gL were not detectable after the first
vaccination, while they were present with two peaks, one week
after the first and second boosts (Figure 10C and E). Total IgG Ab
levels slowly decreased until they were below the detection level of
the assay at the end of the observation period. Yet, at this time
Figure 8. Neutralization of HCMV infection on placental macrophages (Hofbauer cells). Serum samples of RM vaccinated with MVA-gH/
gL-PC, MVA-gH/gL, or MVA-Venus from week 8 after initial vaccination (Figure 6A) were used to determine the titer that prevents 90% infection
(NT90) of ARPE-19 cells and HC with HCMV strain TB40/E. Dashed lines indicate the NT90 values determined for HCMV-IVIg on ARPE-19 and Hofbauer
cells. Dotted lines represent the detection limit. Statistical significance was evaluated using a two-sided Wilcoxon rank-sum test.
doi:10.1371/journal.ppat.1004524.g008
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point, high levels of NAb preventing HCMV infection of EC were
still present in the MVA-gH/gL-PC group (Figure 5B). After the
first boost, both groups had an AI measurement less than 70%.
Subsequently, values decreased between the two boosts and then
rose to 75% in the MVA-gH/gL-PC vaccinated RM, while in
RM vaccinated with MVA-gH/gL, the AI dropped to 42%
(Figure 10D and F). These results indicate that MVA-gH/gL-PC
induces antibodies that are simultaneously neutralizing and of high
avidity, which are maintained for 6 weeks after the final boost,
while the avidity of gH/gL antibodies waned in the same six week
time frame.
All MVA recombinants induce binding antibodies
We noted profound differences in the capacity of different
combinations of gH/gL-PC subunits to support production of
NAb. The absence or lower levels of NAb in mice vaccinated with
MVA-UL128-131, gB or gH/gL in both mice and RM compared
to gH/gL-PC prompted us to investigate if certain MVA
recombinants were incapable of stimulating the production of
BAb. Serum samples from animals vaccinated with MVA
recombinants were evaluated by WB for BAb to gH/gL-PC
subunits or gB. Mice vaccinated with MVA-gH/gL-PC and
MVA-gH/gL-PCD developed BAb to gH, gL, UL128, UL131A,
though not to UL130 (Figure S4). In contrast, MVA-UL128-131
not only induced BAb to UL128 and UL131A, but to UL130 as
well. Mice vaccinated with MVA-gH/gL stimulated BAb to gH
and gL proteins as expected (Figure S4). However, there was far
greater intensity of gL and gH recognition from the gH/gL
construct than MVA-gH/gL-PCD which may reflect steric
interference with immune recognition. In addition, we detected
BAb to gB in MVA-gB or MVA-gBD vaccinated mice (Figure S4).
Interestingly, RM vaccinated with MVA-gH/gL-PC developed
BAb to gH, gL, UL128, and UL130, though not to UL131A
(Figure S4). As observed in mice, MVA-gH/gL elicited BAb to
both gH and gL in RM, with gL showing greater immune
recognition than when expressed from MVA-gH/gL-PC (Figure
S4). Although all single gH/gL-PC subunits exhibited capacity for
an immunological response, only their co-expression led to high
titer NAb that prevented HCMV infection of EC. These results
support the hypothesis that NAb against gH/gL-PC are directed
against a higher order structure or conformational epitopes as a
result of co-expression of five gH/gL-PC proteins.
Discussion
It has been repeatedly confirmed that cell types besides
fibroblasts, notably EC, monocytes, Langerhans cells, and
decidual cells of the placenta influence HCMV natural history
following initial exposure [47,78,79]. Moreover, antibodies that
neutralize HCMV infection of non-fibroblast cell types constitute a
significant proportion of total HCMV NAb [31,40,65]. Accord-
ingly gH/gL-PC has become a focus of HCMV vaccine efforts
since HCMV viral entry into EC and monocytes is absolutely
dependent on the presence of a functional gH/gL-PC [31–33,40].
However, HCMV entry into EC of different origin or modification
than HUVECs or ARPE-19 cells may be gH/gL-PC independent,
since in one case it has been reported that the gH/gL-PC defective
HCMV strain Towne is apparently able to infect and replicate in
fibroblasts, microvasculature endothelial cells, and immortalized
retinal epithelial cells with comparable efficiency [80]. An obstacle
for targeting gH/gL-PC by vaccination is that formation of EC-
specific NAb requires co-expression of all five gH/gL-PC subunits.
This requires that vaccines targeting gH/gL-PC-neutralizing
epitopes co-express all the individual proteins, to ensure cell
surface expression of multimeric protein structures that are needed
to form conformational epitopes [41].
Our previous study provided a template for efficiently
stimulating HCMV gH/gL-PC-specific NAb in vaccinated RM.
BAC-derived MVA was engineered to co-express all five RhCMV
gH/gL-PC proteins, and RM immunized with MVA-RhgH/gL-
PC developed antibodies that neutralized EC infection with a
virulent RhCMV strain[46]. One advantage of this approach is
using bacterial genetics to serially introduce the five genes
encoding gH/gL-PC proteins, which shortens the time for vector
construction. In addition, a single vector for co-expression means
that every vaccine infected cell in vivo can express all combina-
tions of multimeric protein structures that encode epitopes
stimulating NAb. This study extends our work in RhCMV with
a focus on MVA vectors that express two forms of HCMV gH/gL-
PC. We show that both forms of gH/gL-PC stimulate potent
serum Ab titers in murine and primate hosts that neutralize
infection of EC, HC and fibroblasts with different HCMV strains.
Our biochemical studies provided valuable insight into the role
of gH as a membrane anchor and the Ab accessible surfaces of the
complex. The importance of the contribution of gH/gL towards
NAb stimulation by gH/gL-PC is emphasized, because expression
of UL128-130-131A in the absence of gH/gL fails to stimulate
EC-NAb. Using co-IP, in which a mAb to gH or polyclonal
antisera to UL130 results in the pull-down of all five gH/gL-PC
proteins is consistent with the formation of a complex composed of
five subunits. This suggests that both gH and UL130 are accessible
by Ab in the secreted and cellular forms of the gH/gL-PC
(Figures 3A-D). The FC results provide further evidence, but do
not prove that the TM-containing gH/gL-PC is accessible by gH
and UL130 Ab on the cell surface (Figure 4). It is significant that
we detected a cell-associated trimolecular UL128-UL130-UL131A
complex using co-IP after in vitro cell infection with MVA-UL128-
131; since vaccination with MVA-UL128-131 did not cause the
development of NAb preventing HCMV infection of the cell types
we investigated. Paradoxically, UL128-UL130-UL131A proteins
form a sufficiently stable intracellular complex to be detected by
co-IP using the UL130 polyclonal antisera and BAb were
stimulated for each of the UL128-131A subunits. Moreover
UL130 is detectable by FC on the surface of cells infected with
MVA-UL128-131. These data provide evidence that the gH/gL
scaffold facilitates the production of NAb, and that complexes of
UL128-130-131A proteins without gH/gL are insufficient to
induce NAb. MVA expressing only gH/gL stimulated EC-specific
NAb following vaccination in both mice and RM. However, the
titers generated with MVA-gH/gL were one to two orders of
magnitude lower than those generated with either MVA-gH/gL-
PC or MVA-gH/gL-PCD. We conclude that gH/gL-PC com-
posed of five proteins results in higher titer NAb than elicited by
Figure 9. Ab response to HCMV in saliva of vaccinated RM. Oral swab samples from RM vaccinated with MVA-gH/gL-PC, MVA-gH/gL, or MVA-
Venus were analyzed for presence of NAb, HCMV mucosal IgA, and HCMV-IgG. A) NT50 titers in saliva of individual RM measured on ARPE-19 cells
against TB40/E. B and C) HCMV IgG and IgA levels in saliva of vaccine groups (n = 4, analysis of single animals see Sup Figure 3). Floating bar charts
represent time distribution of OD values obtained using HCMV-IgA or HCMV-IgG ELISA assay. Horizontal lines represent means; bars extend from
minimum to the maximum values. Dotted lines represent 99% confidence interval upper limit for mean values obtained in sera from MVA-Venus RM.
Filled triangles indicate time of MVA injections.
doi:10.1371/journal.ppat.1004524.g009
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gH/gL complexes. Our results demonstrate that co-expression of
all five subunits of gH/gL-PC is an efficient mechanism to
stimulate high titer EC-specific NAb. However, alternative
explanations could account for our observations, since the
stoichiometry of the subunits is unknown. For example, gH might
form multiple complexes with different combinations of the other
gH/gL-PC proteins which collectively would co-precipitate with
gH.
MVA-gH/gL-PC and MVA-gH/gL-PCD were generated to
evaluate the impact of the TM domain on the localization of the
Figure 10. HCMV-specific Ab responses and avidity measurements in vaccinated animals. HCMV IgG levels and avidity indices (AI) in
serum samples of mice and RM were determined via ELISA using HCMV particles as antigen. A and B) HCMV IgG levels (GMT, n = 4) and AI measured
in week 7 and 16 mouse serum samples. OD values at 450 nm were normalized to week zero OD. Floating bar chart in B represents the distribution of
AI in different vaccine groups; bars extend from minimum to maximum values. C and E) HCMV IgG levels in individual RM vaccinated with MVA-gH/
gL-PC (C) or MVA-gH/gL (E) using serum samples from different time points. D and F) HCMV-IgG AI values in individual RM vaccinated with MVA-gH/
gL-PC or MVA-gH/gL determined at indicated time points. Horizontal bars represent group means. Filled triangles in A, C and E indicate MVA
vaccinations.
doi:10.1371/journal.ppat.1004524.g010
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complexes, either within the cell or secreted in the medium, and
whether membrane-attached gH/gL-PC with full-length gH or
soluble gH/gL-PCD with TM-deleted gH is a better immunogen
to induce NAb [53,81]. Using a WB approach, we compared
efficiency of expression of gH/gL-PC subunits in the whole cell
when gH was expressed with or without a TM domain and found
no difference in the expression levels of individual gH/gL-PC
subunits. We conclude from our results that the presence or
absence of the TM domain determines if the complex will be
secreted into the medium. Co-IP was used again to discover that
the gH/gL-PCD remains intact in the medium, as we were able to
account for all five subunits using the mAb to gH and a polyclonal
sera against UL130. This finding helps explain why we found
strong NAb responses when vaccinating with MVA-gH/gL-PCD,
since the secreted complex remains intact, and likely stimulates the
generation of the required conformational Ab that we and others
find to be highly neutralizing against EC and fibroblast infection
[41]. We found a similar result with gB, with or without the TM
domain. In that case, in the presence of the TM domain, both the
precursor and membrane-spanning processed forms are detected
intracellularly, although not in the medium. In contrast, in the
case of the expression product without the TM, we found that the
processed C-terminal fragment is expressed both intracellularly
and in the medium. A further independent confirmation of the
influence of the TM on the localization of complexes was carried
out using FC or IF. The TM domain localized the protein to the
cell surface, presumably co-localized with other gH/gL-PC
subunits, while the absence of the TM dramatically reduced cell-
surface expression. These results agree with prior studies by
Ryckman and collaborators investigating the gH/gL-PC and
others who investigated gB secretion requirements [39,53,82,83].
Our results indicate that MVA-gH/gL-PC and MVA-gH/gL-
PCD boost the immune system to produce comparable NAb titers.
However, induction of maximum NAb responses required only
one boost with MVA-gH/gL-PC versus two boosts with MVA-
gH/gL-PCD. The necessity for only two vaccinations with MVA-
gH/gL-PC to induce maximum NAb titers could reduce anti-
vector immunity and simplify the regimen. The lower number of
vaccinations using MVA-gH/gL-PC and faster kinetics to obtain a
maximal NAb response favors that form of the construct for
clinical translation and provided the rationale why it was chosen
instead of MVA-gH/gL-PCD for evaluation in monkeys. Howev-
er, further experiments including long-term studies are required to
conclude if gH/gL-PC with full-length gH is superior to TM-
deleted gH for induction of durable and potent NAb. In the case of
gB, we anticipated that gBD should induce far greater NAb titers
than full-length gB on MRC-5 fibroblasts based on work by
Plotkin and associates and our prior work [53,81,84]. While the
results with fibroblasts and different forms of gB were unexpected,
there were significant differences in the experimental design of our
previous studies as well as those from the Plotkin laboratory. For
instance, the clinical-like strain TB40/E was not previous
employed and the current vaccine virus was derived from an
MVA-BAC as opposed to the cell-culture method that we used in
our previous study.
Our studies contribute to the understanding of the role of gH/
gL-PC as a pivotal target of the host NAb response to HCMV
[33,45]. We demonstrated that NAb induced by MVA-gH/gL-PC
that prevent HCMV infection of EC are at higher titers when
compared to NAb that prevent HCMV infection of fibroblasts.
This is consistent with NAb responses observed after natural
HCMV infection [31,40]. The strength and utility of MVA-gH/
gL-PC as a vaccine is illustrated by its ability to boost the immune
system in two different animal species to reach peak levels of serum
NAb that are higher than those measured from IVIg and roughly
equivalent to CMV-IVIg. The significance of equaling or
surpassing NAb levels in IVIg and CMV-IVIg is to develop an
approach that supersedes the efficacy of these products that failed
to provide adequate protection against congenital HCMV
infection and disease in the recently reported randomized Phase
2 trial [12,13]. Noteworthy are studies with HC, a placental cell of
fetal origin and depot of HCMV that may contribute to
transplacental crossing of HCMV, a potential initiating factor of
congenital infection and disease [5,78]. We observed strong
neutralization of the clinical-like isolate TB40/E which makes the
vaccine a possible means to prevent HCMV infection of the
placenta and/or fetus. Studies of RhCMV infection of pregnant
RM provide an excellent model to investigate the capacity of a
rhesus gH/gL-PC vaccine to limit congenital infection as we
described [85].
We discovered that the MVA-gH/gL-PC vaccine stimulated
EC-specific NAb in saliva of vaccinated RM. Furthermore, we
characterized the Ab class that was found in the saliva as either
mucosal IgA or transudated IgG. Interestingly, the peaks of both
IgA and IgG corresponded to peak NAb titers in two of the four
RM. As anticipated, MVA-gH/gL-PC vaccinated animals showed
more peaks of IgA and IgG than MVA-gH/gL vaccinated
animals. Recently, low level saliva NAb to HCMV were measured
in HCMV-positive individuals, so it is relevant that we measured
comparable NAb after MVA-gH/gL-PC vaccination [73]. While
we could not measure saliva IgA, IgG, or NAb in all RM, this
could be attributable to genetic diversity of the RM we studied,
analogous to findings that not all HCMV-positive humans had
measurable saliva NAb. Moreover, we cannot exclude that some
RM developed saliva NAb titers of biological relevance that were
under the detection limit of the assay. We conclude that MVA-
gH/gL-PC induces NAb in saliva from RM analogous to naturally
infected humans [45,73].
The apparent paradox that MVA-gH/gL-PC induced NAb that
prevented HCMV infection of fibroblasts can be explained by
proposing that a subset of the NAb repertoire generated by MVA-
gH/gL-PC are uniquely directed against gH/gL epitopes without
the accompanying UL128-UL130-UL131A subunit contribution
[41]. It is striking that NAb responses induced by MVA-gH/gL-
PC and MVA-gH/gL that block HCMV infection of fibroblasts
are almost identical to each other in titer and kinetics. This
suggests either that gH/gL subunits as part of the gH/gL-PC
encode neutralizing epitopes similar to those presented by the gH/
gL heterodimer, or that MVA-gH/gL-PC generates both gH/gL
heterodimers as well as the gH/gL-PC that is composed of all five
proteins, with each complex stimulating NAb. Further biochem-
ical studies will clarify which complexes are generated by the
MVA-gH/gL-PC vaccine. The results of this study indicate that
gH/gL-PC can be used to stimulate NAb against both the fusion
and endocytic pathways of virus attachment and entry. An
important contribution highlights that the gH/gL-PC is dispens-
able for Langerhans-type dendritic cells [79]. Nevertheless, the
property of the MVA-gH/gL-PC vaccine to neutralize both
fibroblast and EC infection by HCMV, suggests that it would be
important to test if the MVA-gH/gL-PC vaccine will generate
NAb that will be effective on Langerhans-type dendritic cells. A
recent study has reported on non-infectious particles generated
from HCMV strain Towne that likely express a subset of entry
glycoprotein complexes such as gB, gH/gL, gM/gN but unlikely
intact gH/gL-PC due to a defective UL128-UL131A locus [86].
As expected due to the missing gH/gL-PC and consistent with our
data, they found equivalent levels of NAb measured on fibroblast
or ARPE-19 cells. Comparison with results from our study showed
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that while neutralization on MRC-5 fibroblasts was comparable,
levels of NAb that neutralize infection of ARPE-19 cells were far
lower using the DB preparation than what we measured using the
MVA-gH/gL-PC construct by two orders of magnitude, further
confirming that the UL128-UL131A proteins are required in
combination with gH/gL to induce high titer EC specific NAb.
These results suggest a qualitative difference of DB and MVA-gH/
gL-PC in eliciting NAb that prevent HCMV infection of EC.
The implications of our work on the gH/gL-PC can be
appreciated as a comparable model to the main HIV envelope
glycoprotein complex. HIV research has shown that vaccine
constructs which resemble the antigenic structure of the native
trimeric gp120/gp41 (gp140) envelope spike induce more potent
NAb than those using only gp120 monomers [87]. Our results
complement these findings by showing in mice and RM that a
vaccine approach based on all five gH/gL-PC proteins is
overwhelmingly more effective for high titer NAb induction than
using only protein subsets of the complex. Our findings together
with a recent report from Novartis that demonstrates similar
vaccine properties of the gH/gL-PC using an alphavirus approach
will influence virus vaccine design to optimize the generation of
potent NAb responses by co-expressing multimeric subunits in the
same vector construct [14,88,89].
The strict human host specificity of HCMV precludes
evaluation of protective efficacy by MVA-gH/gL-PC in any
currently used animal model such as RM. In addition, although
the genomes of HCMV and RhCMV are largely co-linear, the two
viruses likely do not share cross-reactive immune responses,
excluding RhCMV as a challenge virus to analyze protection by
HCMV specific immunity in RM [90,91]. We confirmed that sera
of DNA-typed RhCMV-positive RM contain no cross-reactive
NAb that prevent HCMV infection of EC and fibroblasts,
although these same sera neutralize RhCMV infection of primary
rhesus kidney epithelial cells (data not shown). Consequently,
protective efficacy by MVA-gH/gL-PC or any other vaccine
against HCMV can only be evaluated in humans. Our prior work
using MVA as a vaccine vector in which RhCMV-negative RM
were partially protected from acquiring a virulent RhCMV
demonstrates the suitability of this vector system as a candidate
prophylactic vaccine in a relevant herpesvirus model [92]. In that
study and our more recent study involving the rhesus gH/gL-PC
only two administrations of vaccine were required to attain partial
protection [46]. MVA as a vaccine vector is well established and is
in the clinic (NCT01941056) as a therapeutic vaccine to control
HCMV viremia in stem cell transplant recipients and to prevent
HIV infection [93,94].
Our approach of measuring NAb in a primate species after
MVA vaccination comes closest to actual human vaccination
without requiring FDA approval. These studies lay the ground-
work for a step-wise clinical evaluation of the MVA-gH/gL-PC,
either as a single agent or combined with other prominent NAb or
cellular immune targets in HCMV-negative healthy adults,
pregnant women, and adolescents, especially those exposed to
HCMV in a daycare setting [95,96]. While it is unknown if any
HCMV vaccine will prevent reinfection by a second strain of the
virus, our approach has been developed to prevent primary
infection [97]. It will require clinical investigation to assess if a gH/
gL-PC containing vaccine is a successful therapeutic option, either
alone or combined with other vaccine antigens.
In conclusion, we have generated an MVA vaccine vector
expressing five gH/gL-PC subunits that elicited high titer EC and
fibroblast specific NAb in mice and RM. This study will influence
HCMV vaccine design for the following reasons. 1) It outlines a
strategy to effectively prevent the infection of EC and fibroblasts,
primary portals for HCMV replication. 2) HCMV infection is
neutralized on placental macrophages or HC, a known HCMV
depot in the placenta. 3) It introduces a vector system to assemble
all five gH/gL-PC subunits, a requirement for the formation of
conformational neutralizing epitopes for in vivo applications. 4) It
is the first vaccine strategy that targets neutralizing epitopes
formed by the full complement of HCMV gH/gL-PC subunits
expressed from a translational vaccine vector platform with an
extensive clinical safety record. 5) The strategy is equally effective
to elicit high titer NAb in mice and RM. 6) NAb in mice and RM
induced by MVA-gH/gL-PC exceed those of HCMV positive
serum and IVIg preparations. 7) The vaccine strategy induced
NAb preventing infection of EC with titers that exceed those
induced by gH/gL or gB. The pivotal test is to vaccinate HCMV-
negative adolescents with MVA-gH/gL-PC with or without
additional antigens and assess efficacy in preventing infection
and shedding. Equally important is preventing infection in
pregnancy and viral transmission to a fetus. If successful, a gH/
gL-PC vaccine may reduce the morbidity and burden of
congenital HCMV as well as in immunosuppressed hosts from
primary or reactivated infection.
Materials and Methods
Ethics statement
Human placenta. With written informed consent, term (.37
weeks gestation) placentas from HIV-1 and Hepatitis B seroneg-
ative women (.18 years of age) were obtained immediately
following elective caesarian section without labor from Emory
Midtown Hospital in Atlanta, GA. Approval of the study was
granted from the Emory University Institutional Review Board
(IRB). Written informed consent was obtained from donors, and
samples were de-identified prior to handling by laboratory
personnel.
Rhesus Macaques. The animal protocol (#17158) assigned
to this study was approved prior to implementation by the
Institutional Animal Care and Use Committee (IACUC) at
UCDavis, and all procedures conformed to the requirements of
the Animal Welfare Act. This study was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health and in accordance with the recommendations of the
Weatherall report, ‘‘The use of nonhuman primates in research.’’
Activities related to animal care including housing, feeding, and
environmental enrichment were performed in accordance with
Institutional Animal Care and Use Committee (IACUC)-approved
standard operating procedures (SOPs) at the California National
Primate Research Center (http://www.cnprc.ucdavis.edu). Ani-
mals were anesthetized during blood collection, immunization,
and viral challenges. The state of the anesthetized animals was
constantly monitored (movement, respiratory rate, etc.). Analgesics
and veterinary care were provided, as needed, based on the
recommendation of the attending veterinarian. All of the studies
were non-terminal, and all animals were returned to the CNPRC
general colony at the completion of the study.
Mice. The IACUC of the Beckman Research Institute of City
of Hope approved protocol #98004 assigned for this study. All
study procedures were carried out in strict accordance with the
recommendations in the ‘‘Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.’’ Animals
were anesthetized for MVA infections and visually monitored by
the investigator for recovery from anesthesia until the animal was
supine and ambulatory. Animals were observed daily by trained
animal care staff, and animals requiring care were referred to the
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attending veterinarian for immediate care and euthanasia, if
necessary. Analgesics were provided, as needed, at the recom-
mendation of the attending veterinarian. Animals had longitudinal
blood draws following MVA immunizations, and all animals will
be terminated according to the Guide for the Care and Use of
Laboratory Animals and PHS Policy on the Humane Care and
Use of Laboratory Animals. Methods of euthanasia followed the
most current ‘‘Report of the AVMA Panel on Euthanasia’’
(http://www.avma.org/kb/policies/documents/euthanasia.pdf).
Methods were chosen to minimize pain and distress to the mice.
Mice were terminated using a CO2 inhalation chamber.
Viruses and cells
All MVA recombinants, except MVA expressing the fluorescent
marker Venus, were reconstituted from MVA-BAC as described
below [46]. The generation of MVA-Venus has been described
elsewhere [98]. MVA recombinants were propagated on BHK
and CEF cells as described previously [58]. CEF cells (Charles
River Laboratory, Wilmington, MA, USA) were maintained in
serum-free medium (VP-SFM, Invitrogen, Carlsbad, CA, USA).
To generate MVA stocks for in vitro and in vivo experiments,
MVA was prepared from infected BHK cells, purified once by
36% sucrose density ultracentrifugation, and resuspended in
1 mM Tris-HCl (pH 9)[53,92]. MVA stocks were maintained at
280uC.
HCMV strain TB40/E-GFP (kindly provided by Christian
Sinzger, Ulm University, Germany)[49,99] was reconstituted from
BAC-DNA in MRC-5 fibroblasts. HCMV strain TR-GFP was a
gift from Jay Nelson (Oregon Health & Sciences University,
Portland, OR, USA). The isolation of clinical-like HCMV strain
VHL/e has been described elsewhere [63]. ARPE-19 and MRC-5
cells were purchased from ATCC and maintained in Dulbecco’s
minimal essential medium (DMEM, Corning, Corning, NY, USA)
or minimal essential medium (MEM, Corning), respectively,
supplemented with 10% fetal bovine serum (FBS, Hyclone,
Logan, UT, USA). HUVECs were maintained in VascuLife Basal
Medium added with VascuLife EnGS LifeFactors (all from
Lifeline Cell Technology, Frederick, MD, USA). HCMV stocks
were generated following virus propagation in ARPE-19 cells.
Cells were monitored for cytopathic effects (CPE) and re-seeded at
a dilution of 1:2 until 70-80% of the ARPE-19 cells were infected.
Cells were again re-seeded at a dilution of 1:2 and grown for
additional three to four days. Virus particles were concentrated
from clarified medium by ultracentrifugation (700006g for one
hour) over 20% sucrose (w/v) in Tris-buffered saline (0.1 M Tris-
Cl, pH 7.4, 0.1 M NaCl). Concentrated virus was resuspended in
Tris-buffered saline and stored at 280uC. Virus stocks were
titrated on each cell type (ARPE-19, HUVEC, MRC-5, HC) by
immediate-early-1 (IE1) immunostaining to use approximate the
same amounts of plaque forming units (PFU) for the different cell
types in the neutralization assay.
Isolation and culture of HC
In order to isolate HCs, the decidua basalis was dissected from
the placenta, as previously described [100]. The tissue was
thoroughly washed in Hank’s balanced salt solution (HBSS) to
minimize peripheral blood contamination and mechanically
dispersed in complete medium (RPMI supplemented with 10%
FBS, 1 mM L-glutamine, and 1% pen/strep). The minced tissue
was re-suspended in complete medium containing 10% Trypsin/
EDTA (Sigma-Aldrich, St. Louis, MO, USA) for 1 hour, followed
by resuspension in media containing 1 mg/ml collagenase IV
(Sigma-Aldrich), 10 U/ml dispase (Worthington Biochemical
Corp., Lakewood, NJ, USA), and 0.2 mg/ml of DNAse I
(Sigma-Aldrich) and incubated in a shaking water bath at 37uC
for 1 hour. The digested tissue was washed with PBS and passed
through a 70 mm cell strainer (BD-Falcon Biosciences, Lexington,
TN, USA). The mononuclear cell population was isolated by
density gradient centrifugation on Histopaque-1077 (Sigma-
Aldrich). CD14+ Magnetic Cell Sorting was performed using
anti-CD14 magnetic beads (Miltenyi Biotech, Bergisch Gladbach,
Germany) as recommended by the manufacturer. The purity of
the HC population was assessed by CD14 staining and was on
average greater than 97%.
Transfer vector construction
Transfer vectors for gene insertion into the Deletion II site
(Del2) [101], intergenic region 3 (IGR3) [102], and the insertion
site between the essential ORFs G1L and I8R [52] of the MVA-
BAC [60,103] were generated as follows (Figure 1A). Approxi-
mately 700 bp on either side of the MVA insertion site were PCR
amplified from MVA-BAC (Table S5: primer pairs P1/2 and P3/
4 for Del2; P5/6 and P7/8 for IGR3; P9/10 and P11/12 for the
G1L/I8R sites) and cloned via SalI or SpeI into the XhoI or XbaI
restriction sites, respectively, between the two I-CeuI recognition
sequences of plasmid pCeu2 [104]. Then, the kanamycin
resistance gene (KanR) aphAI and the homing endonuclease I-
SceI recognition sequence of plasmid pEPkan-S2 [105] were PCR
amplified with primers that provided a 50 bp duplication of the
MVA insertion site (Table S5: P13/14 for Del2; P15/16 for IGR3;
P17/18 for G1L/I8R). The amplified fragments were introduced
via SalI into the XhoI restriction site between the cloned 700 bp
MVA sequence flanks. Next, the mH5 promoter of plasmid
pZero2-mH5 [58] was PCR amplified with primers that encoded a
multiple cloning site (MCS) (Table S5: P19/20) and cloned via
SpeI into the AvrII site between the left 700 bp MVA sequence
flank and the aphAI-I-SceI cassette (Figure 1A). While the mH5
and MCS sequences were introduced in the sense orientation
between the 700 bp G1L/I8R MVA sequence flanks, they were
cloned in the antisense orientation between the Del2 and IGR3
700 bp sequence flanks (Figure 1A). The final constructs con-
tained an MCS downstream of the mH5 promoter, an aphAI-I-
SceI cassette flanked by a 50 bp duplication, and two 700 bp
MVA sequence flanks at both ends of the transfer constructs
(Figure 1A). The resulting plasmids for gene transfer into Del2,
IGR3, or G1L/I8R, were named pEP-Del2, pEP-IGR3, or pEP-
G1L, respectively. These plasmids allow easy cloning into the
MCS and release of the transfer construct via digestion with I-
CeuI, PmlI, or other restriction sites on the 700 bp MVA
sequence flanks. All final cloned sequences were confirmed by
sequencing. Sequence files for all transfer vectors are available
upon request.
Cloning of HCMV genes
HCMV genes were derived from TB40/E-BAC4 (Accession#
EF999921) [49] and cloned as transfer construct for en passant
mutagenesis [60,103]. Genes were cloned via added PmeI and
AscI restriction sites into EcoRV and AscI restriction sites of the
MCS of the corresponding transfer plasmids. All ORFs were also
cloned with the Kozak sequence GCCGCCACC directly preced-
ing the ATG start codon. For gene transfer of UL128 or UL131A,
synthesized intron-less coding sequences (GenScript, Piscataway,
NJ, USA) were cloned into pEP-Del2 or pEP-IGR3 (Figure 1A),
resulting in pEP-Del2-UL128 or pEP-IGR3-UL131A, respective-
ly. To generate transfer constructs for gH, either as full-length or
TM-deleted coding sequence with C-terminal myc-tag epitope, the
gH ORF was PCR amplified (Table S5: P29/30 or 31/32) from
TB40/E-BAC4 and cloned into pEP-G1L (Figure 1A). The
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C-terminal deletion of gH, removing both the TM and
cytoplasmic domains, corresponded to aa 719-743. The derived
plasmids were termed pEP-G1L-gH or pEP-G1L-gHDTM,
respectively. For insertion of full-length gB or gBD (Fig-
ure 1C)[53], PCR fragments (Table S5: P33/34 and P35/36)
amplified from TB40/E-BAC4 were cloned into the pEP-G1L
plasmid, resulting in pEP-G1L-gB and pEP-G1L-gBD, respective-
ly. The C-terminal deletion of gBD spanned aa 682 to 907 of the
full-length gB protein similar as described [53]. In contrast, the
recombinant gBD protein of the recent clinical phase II trial was
derived from HCMV strain Towne (Accession #M22343)[106].
This gBD protein is a fusion protein of 807 aa with mutagenized
protease cleavage site that was generated by an internal deletion of
the TM domain between aa 715 and 772 of the full-length gB
protein [106]. Towne and TB40/E gB proteins are 99% identical
with a total of seven aa difference over the entire length of the 907
aa protein. Transfer constructs for UL130 and gL were generated
as follows. The mH5 promoter of plasmid pZero2-mH5 [58] was
PCR amplified (Table S5: P19/20) and cloned via the pGEM-T
vector system (Promega, Madison, WI, USA), resulting in pGEM-
T-mH5. Then, UL130 or gL was PCR amplified from TB40/E-
BAC4 [49] (Table S5: 21/22 or P23/24) and cloned (via PmeI and
AscI into the EcoRV and AscI restriction sites) into pGEM-T-
mH5. The aphAI-I-SceI cassette of plasmid pEPkan-S2 [103] was
then PCR amplified (Table S5: P25/26 or P27/28) and
introduced via the KpnI (UL130) or MfeI (gL) restriction sites
within the cloned ORFs, resulting in pEP-UL130 or pEP-gL,
respectively. The final constructs contained the gene sequence
with upstream mH5 promoter and an internal aphAI-I-SceI
cassette flanked by a 50 bp gene duplication of the cloned ORFs
[46]. All cloned sequences were confirmed by sequence analysis.
En passant mutagenesis
Vaccinia virus expression cassettes for each HCMV gene were
recombined into the MVA-BAC by En passant mutagenesis in E.
coli strain GS1783 as described [103]. For insertion of UL128,
UL131A, gH, or gB sequences, the corresponding transfer
constructs (pEP-Del2-UL128, pEP-IGR3-UL131A, pEP-G1L-
gH, or pEP-G1L-gHDTM, pEP-G1L-gBD, pEP-G1L-gB) were
released via I-CeuI and introduced into MVA insertion sites by
initial Red recombination (Figure 1A). After selection of kanamy-
cin resistant recombinants and verification of BAC constructs by
colony-PCR and restriction fragment length analysis (RFLA), the
selection marker was excised by expression of I-SceI to introduce
a double strand-break at the I-SceI recognition site followed by a
second Red recombination between the 50 bp duplications of
the MVA genome flanking the KanR selection marker (Fig-
ure 1A). Recombinants were screened by colony PCR and
RFLA. The correct insertion of each gene was confirmed by
sequencing. To insert UL130 or gL into the MVA-BAC, the
cloned gene sequence with internal aphAI-I-SceI cassette flanked
by a 50 bp gene duplication and upstream mH5 promoter was
amplified via PCR (Table S5: P37/38 or P39/40), and used for
En passant mutagenesis as described [46]. UL130 and gL were
inserted at the left and right BAC vector as shown in Figure 1B.
Transfer vectors as shown for Del2, IGR3, or G1L/I8R in
Figure 1A were not generated for these positions, since they are
uncommon MVA insertion sites (Figure 1A and 1B). The first
Red recombination was performed by 50 bp extensions provided
by the 59 ends of the primers used to amplify the entire insertion
construct (Table S5). The resistance marker was then excised by
a second Red recombination as described above (Figure 1A)
[46].
Virus reconstitution
Virus reconstitution from BAC-DNA was performed on BHK
cells in the presence of helper Fowl pox virus FPV HP1.441 (FPV)
[107] (provided by Bernard Moss, NIAID) similar to published
procedures [46,60,108]. Briefly, BAC-DNA was prepared from E.
coli by alkaline lysis [109]. ,2–4 mg purified BAC DNA was
transfected into BHK cells using X-tremeGENE HP DNA
transfection reagent (Roche, Mannheim, Germany) according to
manufacturer’s instructions. BHK cells were seeded 16–20 h
before transfection at 16104 cells/cm2. Four hours post-transfec-
tion, BHK cells were infected with FPV at multiplicity of infection
(MOI) of 0.1 to initiate virus transcription [46]. Reconstitution was
monitored by expression of GFP from BAC vector constructs [46].
Antibodies
Rabbit polyclonal antiserum against GST-tagged UL128 was
purchased from ATCC [33]. Anti-HCMV gH mAb 11-1-1 or 14-
4b [59], anti-HCMV gB mAb p7-17 [20], and anti-HCMV IE1
mAb p63-27 [110] were kindly provided by W. J. Britt (University
of Alabama, Birmingham, AL, USA). Rabbit polyclonal antisera
to HCMV UL130, UL131A, and gL were raised against the
following peptide sequences: CRMPRTASKPSDGNV (1) and
PWSTLTANQNPSPLWSKLTYC (2) were used to generate
UL130 antisera. The antiserum raised against the first peptide
sequence (1) was used for Immunoblot analysis; and the antiserum
raised against the second UL130 peptide sequence (2) was used for
co-IP. QCQRETAEKNDYYRC was used to generate the UL131
antiserum. Peptide sequence CKQTRVNLPAHSRYGPQAV-
DAR was used to derive the gL antiserum (GenScript).
Immunoblot
Immunoblot to confirm HCMV gene expression from MVA
was performed similar to published standard protocols [46,53].
Briefly, BHK cells (80–90% confluent) were infected with the
MVA recombinants at MOI of 5 and grown for 16–20 h. Infected
cells were harvested, centrifuged at 3006g, and lysed directly by
resuspension in SDS sample buffer (2% SDS, 100 mM dithio-
threitol [DTT], and 125 mM Tris-HCl [pH 8.8]). Proteins were
boiled, electrophoretically separated by SDS-PAGE, and blotted
to a PVDF membrane. Hybridoma supernatant or ascites fluid of
anti-HCMV gH mAb 11-1-1 were used at dilutions of 1/10 or 1/
1000, respectively. UL128, UL130, UL131A, and gL were
detected with rabbit polyclonal antisera at dilutions of 1/3000 to
1/5000. gB proteins were detected with hybridoma supernatant of
anti-gB mAb p7-17 at dilution of 1/10. Proteins were visualized
with secondary antibodies; anti-rabbit or anti-mouse IgG Ab
coupled to horseradish peroxidase (HRP), followed by chemilu-
minescence detection (Pierce ECL WB substrate, Pierce, Rock-
ford, IL, USA). To detect secreted proteins, confluent CEF cells
(80-90%) were infected with the MVA recombinants (MOI of 5)
and grown in serum free medium (VP-SFM; Invitrogen) for 16–
20 h. The medium was harvested, clarified by centrifugation at
10006g, and 20-fold concentrated over Amicon Ultra 4 centrif-
ugal filters (Millipore, Billerica, MA, USA). The concentrate was
mixed with SDS samples buffer. Prepared medium samples and
cell lysates of the infected CEF were analyzed by WB as described
above.
BAb in serum samples from mice and monkeys were detected
via Immunblot as follows. Confluent ARPE-19 cells were infected
with different combinations of replication-deficient Ad vectors
kindly provided by David Johnson (Oregon Health & Sciences
University, Portland, OR, USA)[39]. Cells were co-infected with
20 MOI of Ad expressing the tetracycline (tet)-transactivator (Ad
tet-trans), gH and gL, with Ad tet-trans and UL128, UL130 or
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UL131A, with Ad tet-trans and gB, or with Ad tet-trans alone as a
control. Infected cells were harvested four days post infection,
centrifuged at 3006g, resuspended Tris-HCl buffer (10 mM Tris-
HCl pH 7.9, 1.0 mM EDTA, and Complete Mini protease
inhibitor cocktail tablets (Roche)), and sonicated. Samples were
lysed in SDS buffer, boiled, and used for SDS-PAGE. Proteins
were separate on 8% (gH, gL and gB) or 12% (UL128, UL130 and
UL131A) SDS-polyacrylamide gels using MOPS SDS running
buffer (50 mM MOPS, 50 mM Tris-base, 0,1% SDS, 1.0 mM
EDTA, pH 7.7), transferred to a PVDF membrane, and blocked
over night with PBS-Tween 0.1% (PBS-T)/6% BSA. Inactivated
serum from immunized animals was used as a primary Ab at a
dilution of 1/15000 in PBS-T/5% BSA. Secondary anti-mouse
HRP conjugate (Promega) and anti-monkey HRP conjugate
(KPL, Gaithersburg, MD, USA) were employed in a dilution of
1/20000 in PBS-T/2.5% BSA. Pierce ECL WB substrate was
used for chemiluminescence detection.
Immunoprecipitation
Immunoprecipitation (IP) was performed as follows. BHK cells
(80–90% confluent) were infected with MVA recombinants at
MOI of 5 and harvested after 16–20 h of incubation. All following
steps were performed at 4uC or on ice. Cells were lysed in buffer
containing 0.5% (w/v) Triton X-100, 100 mM Tris-HCl (pH 8.0),
100 mM NaCl, and Complete Mini protease inhibitor cocktail
tablets (Roche). Lysates were cleared by centrifugation at 100006g
and incubated two times for 1 h with recombinant Protein G
Agarose beads (Invitrogen) to remove nonspecific binding. IP was
performed by incubation of pre-cleared lysates for 2 h to over
night with recombinant Protein G Agarose beads coupled to
mouse anti-gH mAb 11-1-1 or UL130 polyclonal antibodies
(UL130 antiserum). As a control for anti-HCMV gH 11-1-1 mAb
or UL130 antiserum, samples were incubated with beads either
coupled to a mouse IgG control Ab (Biolegend, San Diego, CA,
USA) or rabbit UL130 pre-immune serum, respectively. The
beads were washed six times with PBS and boiled in SDS sample
buffer. Immunoprecipitated proteins were detected by immuno-
blot as described above. For immunoprecipitation of secreted
proteins, CEF cells grown in VP-SFM were infected with 5 MOI
of MVA-gH/gL-PCD and incubated for 16–20 h. The medium
was harvested, clarified by centrifugation at 10006g, and 6-fold
concentrated via Amicon Ultra 4 centrifugal filters (Millipore).
Samples were subjected to IP and WB as described. UL130 and
gL after co-IP with rabbit UL130 polyclonal antibodies were
detected via Immunoblot with Clean Blot IP detection reagent
(Pierce) as secondary Ab to reduce the detection signal of the
heavy and light chain of the immunoprecipitating Ab.
Flow cytometry (FC)
For FC detection of gH and UL130 cell surface expression,
confluent BHK cells were infected at an MOI of 5 with MVA
recombinants. Cells were harvested 8 hours post-infection and
washed twice by centrifugation at 3006g and resuspension in FC-
buffer (PBS, 0.1% BSA). Cells were incubated with primary and
secondary Ab diluted in FC-buffer for 30 minutes at 4uC.
Hybridoma supernatants of the primary Ab anti-HCMV-gH mAb
14-4b were used at dilution of 1/10, while UL130 rabbit
antiserum was used at a dilution of 1/100. Secondary antibodies
anti-mouse IgG H+L and anti-rabbit IgG H+L (Alexa Fluor 647,
Life Technologies, Gaithersburg, MD) were applied at 1/2000
dilution. Cells were washed twice in FC buffer between each
incubation step, and after adding secondary Ab, they were
resuspended in FC-buffer for FC. Twenty thousand events were
collected using the Gallios Flow Cytometer (Beckman Coulter,
Miami, FL, USA) and analyzed with FlowJo Software (Tree Star,
Ashland, OR, USA). Cells infected with MVA-Venus used as a
control were first incubated with the primary Ab, followed by the
secondary Ab. GFP expression from MVA recombinants, all
containing a GFP expression cassette (Figure 1B and 1C) [46] was
analyzed as a control to confirm MVA infection of the investigated
cells (data not shown).
Immunofluorescence
Monolayers of BHK cells (80–90% confluent) were infected
with MVA recombinants at MOI of 0.01 and incubated for 16–
20 h. Cells were fixed in 2% paraformaldehyde in PBS, and for
permeabilization treated with 0.2% Triton-X in PBS. Blocking
and staining with primary and secondary Ab was performed for
1 hour in PBS containing 10% FBS. Hybridoma supernatants of
the primary Ab anti-HCMV-gH mAb 14-4b from mouse were
applied at 1/10 dilution. Rabbit anti-Histone H3 (D1H2) mAb
(Cell Signaling, Danvers, MA) was used for IF according to the
manufacturer’s instructions. Fluorophore-coupled secondary anti-
bodies anti mouse IgG Alexa Fluor 555 and anti-rabbit IgG Alexa
Fluor 647 (Life Technologies) were used at 1/500 dilution. Cell
nuclei were stained for 2–5 min with DAPI diluted in PBS. Cells
were washed 2–3 times with PBS after each incubation step.
Immunofluorescence was imaged by the Zeiss LSM510 META
NLO Axiovert 200 M Inverted Microscope (Carl Zeiss, Jena,
Germany). Images were processed with LSM Image Browser from
Zeiss.
Mouse vaccination
Groups of four or eight BALB/cJ mice (Jackson Laboratory, Bar
Harbor, ME, USA) were vaccinated three times with 100 ml of
56107 PFU of purified MVA by i. p. injection from the abdominal
side into the body cavity. This injection method was chosen
because of experience with this procedure. Blood samples were
collected by eye bleed. All mouse handling procedures were
approved by the City of Hope Institutional Animal Care and Use
Committee (IACUC).
Monkey vaccination
Groups of four RM were vaccinated three times six weeks apart
by intramuscular injection with ,56108 PFU of purified MVA as
described [111]. Blood samples and oral swabs to determine NAb
titer were prepared as described [111]. Monkeys used in this study
were genetically outbred RM (Macaca mulatta) from the
California National Primate Research Center (CNPRC), repeat-
edly confirmed to be RhCMV seronegative to prevent cross-
reactivity with HCMV in downstream neutralization assays. Their
age was ,1–2 years at the time of vaccination. The animals were
co-housed in pairs at least two weeks before vaccination, and
remained co-housed until study completion. The IACUC of the
University of California, Davis (UC Davis), which is fully
accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care, approved all animal protocols.
Neutralization assays
HCMV microneutralization assay was performed similar to
published reports [66]. Heat-inactivated sera were serially two-fold
diluted in 100 ml volumes using complete growth medium for
ARPE-19 cells, MRC-5 fibroblasts, HUVECs, or HC depending
on the cell type used in the assay. Dilutions ranged from 1:25 to
1:102400. Diluted serum was mixed with 100 ml of complete
growth medium containing approximately 2400 PFU of HCMV.
After 2 h incubation, mixtures were added in triplicate (50 ml) to
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cells (ARPE-19 cells, MRC-5 fibroblasts, HUVECs, or HC)
seeded the day before at 1.56104 cells/well in a clear bottom
Polystyrene 96-well plate (Corning) that contained 50 ml per
well of complete growth medium. Cells were grown for 48 h and
fixed in methanol/acetone. Infected cells were identified by
immunostaining using mouse anti-HCMV IE1 Ab (p63-27) and
the Vectastain ABC kit (VectorLabs, Burlingame, CA, USA).
The substrate was 3, 39-diaminobenzidine (DAB, VectorLabs).
Plates were analyzed by an automated system using the Axio
Observer Z1 inverted microscope equipped with a linear
motorized stage (Carl Zeiss). IE1 positive nuclei were counted
using ImagePro Premier (Media Cybernetics, Silver Spring,
MD, USA). For each dilution the average number of positive
nuclei in triplicate was calculated. The percent neutralization
titer (NT) for each dilution was calculated as follows: NT= [12
(positive nuclei number with immune sera)/(positive nuclei
number with pre-immune sera)]6100. The titers that gave 50%
neutralization (NT50) or 90% neutralization (NT90) were
calculated by determining the linear slope of the graph plotting
NT versus plasma dilution by using the next higher and lower
NT values that were closest to 50% or 90% neutralization
respectively.
Human sera and IgG
HCMV IgG positive and negative sera were derived from a
pool of seven plasma bags that were donated by volunteers and
tested for HCMV IgG by the City of Hope Blood Bank.
Commercially available HCMV seropositive (Lots BM204234,
BM204360 and BM204371) and negative (Lot BM216642) sera
were purchased from SeraCare Life Sciences (Oceanside, CA,
USA). Intravenous human immunoglobulin (IVIg) was purchased
from Privigen, CSL Behring (Marburg, Germany). Cytogam
(CMV-IVIg) was obtained from the manufacturer (Baxter-
Healthcare Corp., Irvine, CA, USA).
HCMV-TB40/E antigen
HCMV antigen for ELISA assays was prepared as follows.
Approximately 2.56107 ARPE-19 cells showing 80–90% CPE
after HCMV TB40/E infection were harvested in 5 ml of glycine-
saline buffer (0.04 M Glycine, 0.15 M NaCl, 0.01 M NaOH,
pH 9). Cell suspensions were incubated on ice for 4 h. Cells
were dounce-homogenized and cell lysates were clarified at
15006g at 4uC. Supernatants were aliquoted and stored at
280uC until use.
HCMV IgG ELISA
Microtiter wells (EIA/RIA Plates, Costar, Corning) were coated
overnight with 100 ml HCMV TB40/E antigen prepared as
described above. Wells were washed three times with PBS and
blocked for 2 h with PBS containing 1% BSA. Wells were washed
again in PBS containing 0.1% Tween20 (wash-buffer) and serum
samples diluted 1/100 in sample buffer (PBS, 0.1% Tween 20, 1%
BSA) were added in quadruplicate and incubated for 2 h. Two
wells of each quadruplicate were washed either in wash-buffer or
wash buffer containing 6 M urea; then, all wells were washed
again two times in wash-buffer. Wells were incubated with
secondary anti-mouse HRP conjugate (Promega) or anti-monkey
HRP conjugate (KPL) and then developed with TMB substrate
reagent. OD values at 450 were measured and normalized
based on week zero OD. Avidity index (AI) values were
expressed as percentage of the ratio of OD in wells washed with
wash buffer containing 6 M urea/OD in wells washed with wash
buffer.
Oral swab total and HCMV-specific IgG
Evaluation of total IgG titer in oral swab samples was performed
using an ELISA kit for human/monkey IgG (Mabtech, Stock-
holm, Sweden) according to the manufacturer’s instructions. Oral
swab samples were diluted 1/240 in sample buffer (PBS, 0.1%
Tween 20, 1% BSA). Standard or sample dilutions were added in
duplicate. Total IgG concentration was derived from the standard
curve. HCMV-specific IgG assay was performed as above using
CMV-TB40/E antigen coated plates. Oral swab samples were
diluted 1/24 in sample buffer and added in duplicate. CMV-IgG
levels were expressed as OD at 405 nm.
Oral swab total and CMV-specific IgA
Evaluation of total IgA titer in oral swab samples was performed
using ELISA for monkey IgA (Mabtech) according to the
manufacturer’s instructions. For the assay, oral swab samples
were diluted 1/240 in sample buffer. Standard or sample dilutions
were added in duplicate wells. Total IgA concentration was
derived from the standard curve. CMV-specific IgA assay was
performed as above but using CMV-TB40/E antigen coated
plates. Oral swab samples were diluted 1/24 in sample buffer and
added in duplicate wells. CMV-IgA levels were expressed as OD
at 405 nm.
Supporting Information
Figure S1 Cell surface imaging of gH expressed from
MVA recombinants.Monolayers of BHK cells were infected at
a low multiplicity of infection with the indicated MVA
recombinants (MVA-gH/gL-PC, MVA-gH/gL-PCD, and
MVA-gH/gL). Cells were fixed 16 h after the infection and
either left untreated (non-permeabilized) or permeabilized.
Staining was performed with mouse anti-HCMV gH mAb 14-
4b and anti-mouse Alexa Flour 555 secondary Ab. Cell nuclei
were stained with DAPI. Immunofluorescence was imaged by
confocal microscopy. GFP expression from the MVA vectors (all
BAC-reconstituted MVA expressed GFP due to the vector
construction (Figure 1) was detected to localize foci of virus
spread. Staining of Histone H3 using anti-Histone H3 rabbit
mAb and secondary Alexa Flour 647 Ab was performed as a
control to determine if non-permeabilized cells were non-
penetrable by antibodies and permeabilized cells were penetrable
by antibodies.
(TIF)
Figure S2 Distance tree of different HCMV clinical and
laboratory strains. Protein sequences of different HCMV
laboratory strains (AD169, Davis and Towne) and clinical isolates
that have been passaged to a limited extent in the laboratory
(Merlin, TB40/E, Toledo, TR and VR1814) were analyzed using
COBALT multiple alignment tool and a phylogenetic tree was
build using Fast Minimum Evolution algorithm and applying a
0.85 maximum sequence difference and the Grishin evolutionary
distance model.
(TIF)
Figure S3 Salivary IgG and IgA responses in individual
RM vaccinated with MVA-gH/gL-PC or MVA-gH/gL.
Oral swab samples from immunized RM were analyzed using
commercial IgG/IgA ELISA kits for measuring total Ab levels.
IgG/IgA ELISA assays using CMV TB40E antigen coated plates
were used to determine CMV-specific IgG/IgA levels. A and B)
Oral swab mucosal IgA levels in RM vaccinated with MVA-gH/
gL-PC or MVA-gH/gL. C and D) CMV-mucosal IgA levels in
oral swabs from MVA-gH/gL-PC or MVA-gH/gL vaccinated
HCMV gH/gL-Pentamer Complex Vaccine
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RM. E and F) Oral swab IgG levels in RM vaccinated with
MVA-gH/gL-PC or MVA-gH/gL. G and H) CMV-IgG levels
in oral swabs from MVA-gH/gL-PC or MVA-gH/gL vaccinat-
ed RM. Dotted lines in A, B, E and F represent the detection
limit of the assay, dashed lines in C, D, G and H represent the
upper limit of the 99% confidence interval for the mean values
obtained in the MVA-Venus RM. Filled triangles indicate MVA
injections.
(TIF)
Figure S4 Binding antibodies (BAb) of HCMV proteins
in sera from vaccinated animals. Serum preparations from
mice and monkeys vaccinated with MVA recombinants (MVA-
gH/gL-PC, MVA-gH/gL-PCD, MVA-gH/gL, MVA-UL128-
131, MVA-gB, MVA-gBD, MVA-Venus) were used at a dilution
of 1/15000 to detect gH, gL, UL128, UL130, UL131A or gB
expressed from Ad vectors in ARPE-19 cells by WB (see
Material and Methods for detailed WB description). Ad tet-trans
was analyzed as a control. Shown are WBs using one
representative serum sample from one mouse or RM per
vaccine group (see Figure 3 and 4 for vaccine groups) obtained
after 3 MVA vaccinations (mice) or 2 MVA immunizations
(RM) (see Figure 3 and 4 for vaccination timelines). Arrows
indicate the expected protein bands. A) BAb in MVA
vaccinated BALB/cJ mice. B) BAb in RM vaccinated with
MVA recombinants.
(TIF)
Table S1 Analysis of mouse serum NT50 levels on
ARPE-19, MRC-5 fibroblasts and HUVECs after 3 MVA
vaccinations. Groups of 4 BALB/c mice were vaccinated 3
times at week 0, 4 and 8 using the MVA constructs shown in the
table. NAb levels were evaluated on ARPE-19, MRC-5 fibroblasts
and HUVECs using serum samples collected at 3, 7, 11 and 16
weeks after the first vaccination. Shown in the table is the average
serum NT50 and standard deviation.
(DOCX)
Table S2 Analysis of RM serum NT50 levels on ARPE-
19, MRC-5 fibroblasts and HUVECs after 3 MVA
vaccinations. Groups of 4 RM were vaccinated 3 times at week
0, 6 and 12 with MVA-gH/gL-PC, MVA-gH/gL or MVA-Venus.
NAb levels were evaluated on ARPE-19, MRC-5 fibroblasts and
HUVECs using serum samples collected at different time points
(Figure 6A). Listed in the table are individual animal measure-
ments and group average NT50.
(DOCX)
Table S3 RM Serum NT90 levels measured on ARPE-19
cells and HC after 2 MVA vaccinations. Shown in the table
is the serum NT90 obtained on ARPE-19 and HC using RM
serum collected 8 weeks after the first vaccination.
(DOCX)
Table S4 Analysis of saliva NT50 levels in MVA-gH/gL-
PC vaccinated RM measured on ARPE-19 cells. The table
shows longitudinal variation of NT50 titers in saliva samples of
individual RM measured on ARPE-19 cells against HCMV
TB40/E.
(DOCX)
Table S5 Primer list. Shown in the table is the list of primers
used to generate the transfer vectors for gene insertion into the
Del2, IGR3, G1L and I8R of the MVA-BAC (See Materials and
Methods for details).
(DOCX)
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